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Abstract 
Previous evidence showed abnormal posterior sources of resting state delta (<4Hz) 
and alpha (8-12 Hz) rhythms in patients with Alzheimer’s disease with dementia (ADD), 
Parkinson’s disease with dementia (PDD), and Lewy body dementia (DLB), as cortical 
neural synchronization markers in quiet wakefulness. Here we tested the hypothesis of 
additional abnormalities in functional cortical connectivity computed in those sources, in 
ADD, considered as a “disconnection cortical syndrome”, in comparison with PDD and 
DLB. 
Resting state eyes-closed electroencephalographic (rsEEG) rhythms had been 
collected in 42 ADD, 42 PDD, 34 DLB, and 40 normal healthy elderly (Nold) subjects. 
eLORETA freeware estimated the functional lagged linear connectivity (LLC) from rsEEG 
cortical sources in delta, theta, alpha, beta, and gamma bands. Area under Receiver 
operating characteristic (AUROC) curve indexed the classification accuracy between Nold 
and diseased individuals (only values > 0.7 were considered). 
Interhemispheric and intrahemispheric LLCs in widespread delta sources were 
abnormally higher in ADD group and, unexpectedly, normal in DLB and PDD groups. 
Intrahemispheric LLC was reduced in widespread alpha sources dramatically in ADD, 
markedly in DLB, and moderately in PDD group. Furthermore, the interhemispheric LLC in 
widespread alpha sources showed lower values in ADD and DLB than PDD. At the 
individual level, AUROC curves of LLC in alpha sources exhibited better classification 
accuracies for the discrimination of ADD vs. Normal elderly (Nold) individuals (0.84) than 
for DLB vs. Nold (0.78) and PDD vs. Nold (0.75). 
Functional cortical connectivity” markers in delta and alpha sources suggest a more 
compromised neurophysiological reserve in Alzheimer’s than Lewy body dementia, at 
both group and individual levels. 
3 
 
Introduction 
 
Differential diagnosis of Alzheimer’s disease (ADD), Parkinson’s disease(PDD), and 
Lewy body dementia (DLB)  is important as patients with DLB and PDD may be 
considerably more sensitive to adverse effects of neuroleptic (Ballard et al., 1998) and 
may exhibit faster disease progression (Olichney et al., 1998) and different responses to 
acetylcholinesterase inhibitors (Levy et al., 1994); furthermore, these diseases have at 
least in part different etiologies and might require specific disease-modifying regimens 
when available (Bhat et al., 2015; Karantzoulis and Galvin, 2013; McKeith et al., 2005).  
In the light of the new international criteria (Albert et al., 2011; Dubois et al., 
2014), AD may be discriminated from PD and DLB by higher abnormalities in the 
cerebrospinal fluid (CSF) “Aphospho-tau” ratio and deposition of A42 or tau in the 
brain as shown by positron emission tomography (PET) mapping. Other useful 
topographic biomarkers of AD neurodegeneration are hypometabolism of the posterior 
cerebral cortex as revealed by 18F-Fluorodeoxyglucose-positron emission tomography 
(FDG-PET) and hippocampus atrophy on magnetic resonance imaging (MRI), (Albert et al., 
2011; Dubois et al., 2014; McKhan et al., 2011). PET or SPECT scan of dopamine 
transporter can also be used for the differential diagnosis between PDD and DLB on the 
one side and ADD on the other side (Zhu et al., 2014). Promising candidate topographic 
biomarkers are those derived from the analysis of resting state eyes-closed 
electroencephalographic (rsEEG) rhythms (Breslau et al., 1989; Briel et al., 1999; 
Giaquinto and Nolfe, 1986). The recording of rsEEG rhythms is non-invasive and cost-
effective. Markers of rsEEG rhythms may probe the neurophysiological “reserve” in 
patients with dementing disorders; the latter is defined as the residual ability of the brain 
to ensure (1) the synchronization of neural activity at different spatial scales and 
frequencies from small cellular populations to large regions and (2) the coordination of 
this synchronization across subcortical and cortical neural networks (Babiloni et al., 
2016a). The neurophysiological reserve can thus be considered as one of the dimensions 
of the brain reserve (Stern, 2017). In this line, the assessment of the neurophysiological 
“reserve” in neurological patients can be based on two main classes of markers derived 
from rsEEG rhythms, namely the cortical neural “synchronization/desynchronization” at 
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given frequency bands and “functional cortical connectivity”, defined as the 
interdependence of cortical neural synchronization/desynchronization Intrahemisphericly 
and Interhemisphericly (Babiloni et al., 2015a). Practically, this connectivity can be 
computed from rsEEG rhythms recorded at electrode pairs or estimated in coupled 
cortical sources (Babiloni et al., 2015a).  
Functional cortical connectivity might be especially relevant to understand the 
pathophysiological mechanisms underlying different dementing disorders, as human 
cognition is based on a coordinated neurotransmission within large-scale networks 
(D’Amelio and Rossini 2012; Pievani et al., 2011). Clinically, ADD typically presents with a 
major amnesic syndrome although there may be, less commonly linguistic, visuospatial, 
and visual disease variants (Dubois et al., 2014). PDD and DLB manifest with attentional, 
verbal, and executive cognitive deficits in association with motor manifestations such as 
bradykinesia, tremor, postural instability, and rigidity (Aarsland et al., 2003; Buter et al., 
2008; Dubois and Pillon, 1997; Emre et al., 2007; Huber et al., 1989; Hughes et al., 2000; 
Levy et al., 2000; Walker et al., 2015; Wolters, 2001). Motor symptoms substantially 
precede cognitive deficits in PD but not DLB where the onset of motor symptoms is either 
at the same time as the cognitive deficits or emerges later. Furthermore, DLB is primarily 
characterized by visual hallucinations, REM sleep disturbances, and diurnal cognitive 
fluctuation (McKeith et al., 2005). It can be speculated that those different clinical 
phenotypes are related to different abnormalities in “synchronization/desynchronization” 
and “cortical functional connectivity” markers of rsEEG rhythms. 
Concerning the “synchronization/desynchronization” markers, previous studies 
showed that compared normal healthy elderly (Nold) subjects, ADD patients are 
characterized by lower power density in posterior alpha (8-12 Hz) and beta (13-30 Hz) 
rhythms (Babiloni et al., 2006a; Dierks et al., 1993, 2000; Huang et al. 2000; Jelic et al., 
2000; Jeong, 2004; Ponomareva et al., 2003). Furthermore, ADD patients exhibit higher 
power density in widespread delta (<4 Hz) and theta (4-7 Hz) rhythms (Brassen and Adler, 
2003; Kogan et al., 2001; Onofrj et al., 2003; Reeves et al., 2002; Rodriguez et al., 2002; 
Valladares-Neto et al., 1995). Similarly, PDD patients demonstrate widespread high power 
density in delta and theta rhythms and some reduction of alpha power density (Bonanni 
et al., 2008; Bosboom et al., 2006, 2009; Caviness et al., 2016; Fünfgeld, 1995; Kamei et 
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al., 2010; Melgari et al., 2014; Neufeld et al., 1988, 1994; Pugnetti et al., 2010; Serizawa et 
al., 2008; Soikkeli et al., 1991; Stam et al., 2006). DLB patients are characterized by diffuse 
and fluctuating delta and theta power density with some frequency spectra differences 
from those observed in PDD and ADD; these EEG features are described as a “supportive” 
biomarker in the clinical diagnostic guidelines (Andersson et al., 2008; Bonanni et al., 
2008, 2015, 2016; Kai et al., 2005; McKeith et al., 2005, 2017; Onofrj et al., 2003; Walker 
et al., 2000a, b).  
As far as the “functional cortical connectivity” markers are concerned, previous 
studies showed that compared with Nold subjects, ADD patients point to lower spectral 
coherence between electrode pairs in posterior alpha (8-12 Hz) and beta (13-20 Hz) 
rhythms (Adler et al., 2003; Anghinah et al., 2000; Besthorn et al., 1994; Dunkin et al., 
1994; Fonseca et al., 2011, 2013; Jelic et al., 1997, 2000; Knott et al., 2000; Leuchter et al., 
1987, 1992; Locatelli et al., 1998; Pogarell et al., 2005; Sloan et al., 1994). However, these 
effects are topographically variable being observed in temporo-parieto-occipital electrode 
pairs in some studies (Adler et al., 2003; Locatelli et al., 1998; Jelic et al., 1997, 2000) yet 
in other studies in frontocentral electrode pairs (Besthorn et al., 1994; Fonseca et al., 
2013; Leucther et al., 1994). Furthermore, some studies report a coherence decrease of 
rsEEG rhythms at low frequencies, especially at central electrodes in the theta band (Adler 
et al., 2003; Knott et al., 2000). Other studies report an increase in widespread delta 
coherences (Babiloni et al., 2010; Locatelli et al., 1998) or a quite complex topographical 
pattern of coherence increases and decreases (Sankari et al., 2011). Moreover, studies 
using alternative techniques measuring rsEEG functional coupling show a decrement of 
synchronization likelihood in frontoparietal alpha rhythms in ADD and mild cognitive 
impairment patients compared with Nold subjects (Babiloni et al., 2004, 2006b). Finally, 
global beta phase lag index across all scalp electrode pairs was lower in ADD patients 
compared with Nold subjects (Stam et al., 2007).  
The above rsEEG results have received some clinical validation. In AD individuals, 
there are correlations between rsEEG coherences and scores of mini-mental state 
examination (MMSE), as a measurement of global cognitive status and language, 
memory, and constructional praxis (Fonseca et al., 2011, 2013). These correlations are 
negative for delta and theta bands and positive for alpha and beta bands (Fonseca et al., 
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2011). Furthermore, there is an association between rsEEG coherence and periventricular 
white matter hyperintensities (PVHs) interpreted as due to impairment of neural 
transmission (Leuchter et al., 1992, 1994).  
In PD individuals, abnormal functional cortical connectivity is consistently revealed 
by rsEEG coherence between electrode pairs. Compared to Nold subjects, PD patients 
show lower local intrahemispheric parietal alpha coherence (Moazami-Goudarzi et al., 
2008). Furthermore, intrahemispheric cortico-cortical frontoparietal alpha and beta 
coherences are positively correlated with the severity of PD motor symptoms in the 
patients (Silberstein et al., 2005). Both L-dopa regimen and electrical stimulation of 
subthalamic nucleus reduce those coherences in association with an improvement of 
motor symptoms (Silberstein et al., 2005). Other evidence reveals a positive correlation 
between PD duration and beta coherence between rsEEG rhythms recorded in 
supplementary motor and primary motor areas (Pollok et al., 2013). 
Concerning the relationship between functional cortical connectivity and 
cognition, PD patients with cognitive deficits demonstrate a positive correlation between 
decreased intrahemispheric frontoparietal alpha coherence and executive dysfunctions 
(Teramoto et al., 2016). Furthermore, PDD patients exhibit greater interhemispheric 
frontal alpha-beta and intrahemispheric fronto-occipital beta coherences than ADD 
patients do (Fonseca et al., 2013).  
In line with ADD and PDD patients, DLB subjects show a derangement of functional 
cortical connectivity derived from rsEEG rhythms. Global delta and alpha coherences 
across all electrode pairs are reported as higher in DLB than ADD patients (Andersson et 
al., 2008). In contrast, global alpha phase lag index across all electrode pairs is lower in 
DLB than both ADD and Nold subjects (van Dellen et al., 2015). Furthermore, 
intrahemispheric fronto-temporo-central delta and theta coherences are higher in DLB 
than ADD patients, while temporo-centro-parieto-occipital beta (not alpha) coherences 
are lower in the former compared to the latter (Kai et al., 2005). Finally, posterior-to-
anterior directed information flow is lower in alpha in DLB patients and decreases in beta 
in ADD patients (Dauwan et al., 2016a).  
The above measurements of rsEEG functional connectivity have been successfully 
used to discriminate ADD, PDD, and DLB individuals. Global delta and alpha coherences 
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between electrode pairs allow for a classification accuracy (AUROC- curve) of DLB 
individuals compared with ADD and Nold subjects of 0.75-0.80 and 0.91-0.97 (e.g. 1 = 
100% of accuracy), respectively (Andersson et al., 2008). A complex step-wise procedure 
using 20 discriminant scalp rsEEG power density and coherences as an input to a 
statistical pattern recognition method shows a classification accuracy (AUROC curve) of 
0.90 between ADD and Nold individuals as well as between ADD and PDD subjects 
(Engedal et al., 2015).  Another recent study in relatively small populations of ADD, 
PDD/DLB, and frontotemporal dementia patients used 25 discriminant scalp rsEEG power 
density and functional cortical connectivity (i.e. Granger causality) variables as an input to 
support vector machine, reaching a classification accuracy of 1.0 (Garn et al., 2017). 
Paradoxically, another study combining quantitative rsEEG variables (including those of 
functional cortical connectivity) with neuropsychological, clinical, neuroimaging, 
cerebrospinal fluid, and visual EEG data reached “only” a classification accuracy of 0.87 in 
the discrimination between ADD, PDD, and DLB individuals (Dauwan et al., 2016b).  
The inter-study variability of the mentioned results might be due to (1) the 
analysis of rsEEG data at scalp electrodes pairs and (2) the use of fixed frequency bands 
for all subjects, regardless the frequency “slowing” of rsEEG rhythms in dementia. To 
mitigate those potential confounding effects on “synchronization/desynchronization” 
markers, we have recently combined (1) a source estimation technique called exact low-
resolution brain electromagnetic tomography (eLORETA; Pascual-Marqui, 2007a) and (2) 
an analysis of rsEEG rhythms based on the “individual alpha frequency peak” (IAF; 
Klimesch, 1996, 1999; Klimesch et al., 1998). With this approach, we tested the 
hypothesis that eLORETA source activity of scalp rsEEG rhythms might reflect different 
features of abnormal cortical neural synchronization/desynchronization in ADD, PDD, and 
DLB patients (Babiloni et al., 2017). To that aim, datasets in 42 PDD, 34 DLB, 42 ADD, and 
40 Nold subjects were analyzed (demography, education, and the MMSE score did not 
differ between the patients’ groups). Results are summarized in the following (Babiloni et 
al., 2017). The IAF exhibits a marked frequency slowing in the PDD and DLB groups and a 
moderate frequency slowing in the ADD group. Compared with Nold subjects, the three 
patients’ groups show lower posterior alpha source activities. This effect is dramatic in the 
ADD group, marked in the DLB group, and moderate in the PDD group. The three patients’ 
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groups also exhibit higher occipital delta source activities. This effect is greatest in the 
PDD group, marked in the DLB group, and moderate in the ADD group.  
Concerning the individual level, the posterior delta and alpha sources permitted 
good classification accuracies (AUROC curve) ranging 0.85-0.90 between the Nold subjects 
and patients as well as between ADD and PDD patients (Babiloni et al., 2017). Those 
findings unveiled different spatial and frequency features of the cortical neural 
synchronization/desynchronization underpinning brain arousal in quiet wakefulness in 
ADD, PDD, and DLB patients where the DLB group showed features in between the ADD 
and PDD groups.  
Keeping in mind those findings and considerations, the present retrospective 
exploratory study re-analyzed that original rsEEG database used in the stude of Babiloni 
and colleagues (2017) to derive complementary “functional cortical connectivity” 
markers. We compared the intrahemispheric and interhemispheric lagged linear 
connectivity between cortical sources of rsEEG rhythms in Nold, ADD, PDD, and DLB 
subjects. The comparison was made both at the group and the individual level. The core 
hypothesis was that at both levels, “functional cortical connectivity” markers were 
globally more altered in ADD patients whose disease has been considered as a cortical 
“disconnection syndrome” (Besthorn et al., 1994; Bokde et al., 2009; Dunkin et al., 1995; 
Leuchter et al., 1994; Reuter-Lorenz and Mikels, 2005; Teipel et al., 2016). 
 
Materials and Methods 
Details on the subjects, diagnostic criteria, rsEEG recording, and preliminary data 
analysis were reported in the reference paper (Babiloni et al., 2017). In the following 
sections, we provide a short description of those methodological procedures for readers’ 
convenience. 
 
Subjects and diagnostic criteria 
We used the rsEEG data of an international archive, formed by clinical, 
neuropsychological, and electrophysiological data in 40 Nold, 42 ADD, 42 PDD, and 34 DLB 
subjects. The four groups (i.e. PDD, ADD, DLB, and Nold) were carefully matched for age, 
gender, and education. The three groups of patients with dementia were also carefully 
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matched for the MMSE score (Folstein et al. 1975). Table 1 reports details of the above 
variables.  
Insert here Table 1 
Probable ADD was diagnosed according to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR; American Psychiatric 
Association) and the National Institute of Neurological Disorders and Stroke–Alzheimer 
Disease and Related Disorders (NINCDS–ADRDA) working group (McKhann et al., 1984).  
The ADD patients underwent general medical, neurological, and psychiatric 
assessments. They were also rated on some standardized clinical scales that included 
MMSE (Folstein et al., 1975), clinical deterioration rate (CDR; Hughes et al., 1982), 15-item 
geriatric depression scale (GDS; Yesavage et al., 1983), Hachinski Ischemic Score (HIS; 
Rosen et al., 1980), and Instrumental Activities of Daily Living scale (IADL; Lawton and 
Brodie, 1969). Neuroimaging diagnostic procedures (MRI) and laboratory analyses were 
carried out to exclude other causes of progressive or reversible dementias, in order to 
form a relatively homogenous ADD patient group. Computed Tomography (CT) was 
performed in those patients with contraindications to MRI. 
Inclusion criteria were as follows: (1) objective impairment on neuropsychological 
evaluation, as defined by performances 1.5 standard deviations (SD) from the mean value 
for the age- and education-matched controls in at least two cognitive domains; (2) clinical 
dementia rating score higher than 0.5; and (3) abnormal activities of daily living as 
attested by the history and evidence of independent living.  
Exclusion criteria included any evidence of (1) frontotemporal dementia, 
diagnosed according to criteria of Lund and Manchester Groups (1994), (2) vascular 
dementia, diagnosed according to NINDS-AIREN criteria (Roman et al., 1993), (3) 
extrapyramidal syndromes, (4) reversible dementias (including pseudodementia of 
depression), and (5) Lewy body disease associated dementia. A battery of 
neuropsychological tests assessed general cognitive performance in the domains of 
memory, language, executive function/attention, and visuoconstruction abilities (for 
details see Babiloni et al., 2017). Concerning psychoactive medications, most of the 
enrolled ADD patients (89%) followed a long-term treatment with standard daily doses of 
acetylcholinesterase inhibitors (AChEIs ; e.g., donepezil 5–10 mg/die or rivastigmine 
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3mg/die; galantamine 16–36 mg/die). About 2% received N-Methyl-D-aspartate receptor 
(NMDAR) antagonists (e.g., memantine). About 24% non-regularly took antidepressant or 
sedatives (e.g., fluoxetine, benzodiazepines) drugs. 
The diagnosis of PD was based on a standard clinical assessment of tremor, 
rigidity, and bradykinesia (Gelb et al., 1999). As measures of severity of motor disability, 
the Hoehn and Yahr stage (Hoehn and Yahr, 1967) and the Unified Parkinson Disease 
Rating Scale-III (UPDRS-III; Fahn and Elton, 1987) for extrapyramidal symptoms were used. 
A diagnosis of PDD was given to the patients with a history of dementia (inclusion criteria 
as for ADD) preceded by a diagnosis of PD for at least 12 months.  
On the basis of clinical features and neuroradiological findings, exclusion criteria 
for PDD included the following forms of parkinsonism: (1) DLB (McKeith et al., 1996), (2) 
secondary parkinsonism, including drug-induced parkinsonism, (3) cerebrovascular 
parkinsonism, and (4) atypical parkinsonism with absent or minimal responses to 
antiparkinsonian drugs.  
All PDD patients underwent a battery of clinical scales including the 
Neuropsychiatric Inventory (NPI; Cummings et al., 1994), the scale for the assessment of 
Behavioral and Psychological Symptoms of Dementia (BPSD), the MMSE, the Dementia 
Rating Scale-2 (DRS-2; Jurica et al., 2001), the Epworth Sleepiness Scale (ESS) to estimate 
subjective sleep disturbances, and the Alzheimer’s Disease Cooperative Study for the 
Activities of Daily Living (ADCS-ADL). All PDD subjects also underwent a battery of 
neuropsychological tests (for details see Babiloni et al., 2017). Concerning psychoactive 
medications, most of the enrolled PDD patients (79%) followed a treatment with standard 
doses of dopamine agonists (levodopa, carbidopa, entacapone, pramipexole, 
apomorphine, tolcapone, rasagiline or rotigotine). About 45% assumed AChEIs 
(rivastigmine, donepezil, galantamine) and about 5% received NMDAR antagonists 
(memantine). Furthermore, about 42% regularly took  anti-depressant (selective 
serotonin reuptake inhibitor: sertaline, citalopram, paroxetine; monoamine oxidase 
inhibitor: selegiline; noradrenergic and specific serotonergic antidepressant: mirtazapine; 
serotonin antagonist and reuptake inhibitor: trazodone; serotonin-norepinephrine 
reuptake inhibitor: venlafaxine). Finally, about 8% of them took benzodiazepine sedatives 
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(lorazepam, clonazepam) and 37% of them took anti-psychosis (quetiapine, clozapine, 
aripiprazole). 
Dementia was diagnosed in the DLB patients as for the ADD and PDD patients (see 
above inclusion and exclusion criteria). The diagnosis of probable DLB was carried out in 
agreement with the consensus guidelines by McKeith and colleagues (2005). Concerning 
the detection of the core and suggestive features of DLB, the NPI item-2 investigated the 
occurrence frequency and the severity of hallucinations (Cummings et al., 1994). Frontal 
Assessment Battery (FAB; Dubois et al., 2000) and Clinician Assessment of Fluctuations 
(Walker et al., 2000a) were included to investigate, respectively, the severity of frontal 
dysfunctions and the presence and severity of cognitive fluctuations. UPDRS-III (Fahn and 
Elton, 1987) assessed the presence and severity of extrapyramidal signs. The presence or 
absence of rapid eye movement (REM) sleep behavior disorder (RBD) was determined 
according to minimal International Classification of Sleep Disorders criteria (1992). All DLB 
subjects also underwent a battery of neuropsychological tests (for details see Babiloni et 
al., 2017). Concerning psychoactive medications, half of the enrolled DLB patients (50%) 
followed a treatment with standard doses of dopamine agonist (levodopa, carbidopa, 
entacapone). About 25% assumed AChEIs (rivastigmine) and about 13% received NMDAR 
antagonists (memantine). Furthermore, about 38% regularly took anti-depressant (SSRI: 
citalopram, paroxetine). Finally, about 13% of them took benzodiazepine sedatives 
(lorazepam) and most of them (63%) took anti-psychosis (quetiapine, clozapine) drugs. 
In all ADD, PDD and DLB patients, drugs were suspended for about 24 h before 
EEG recordings. This did not insure a complete washout of the drug -longer periods would 
not have been applicable for obvious ethical reasons-, but made it comparable the drug 
condition in the ADD, PDD and DLB patients. 
All Nold subjects underwent a cognitive screening (including MMSE and GDS) as 
well as physical and neurological examinations to exclude any dementia or major 
cognitive deficit or psychiatric disorder.  
 
rsEEG recordings and preliminary data analysis 
The rsEEG data were recorded in the morning while subjects kept their eyes closed 
in a relaxed state, not moving or talking. About five minutes of rsEEG data were recorded 
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(128 Hz or higher sampling rate, with related antialiasing bandpass between 0.01 Hz and 
100 Hz) from 19 scalp electrodes positioned according to the 10–20 System (i.e. Fp1, Fp2, 
F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, and O2). A ground electrode 
was located in the frontal region. Electrodes impedances were kept below 5 Kohm. 
Horizontal and vertical electro-oculographic activities (0.3-70 Hz bandpass) were also 
recorded to monitor blinking and eye movements. Table 1 in the Supplementary material 
reports details about sampling rates, time constants, and digital EEG systems used in all 
Recording Units of the present international Consortium. Figure 1 show representative 
EEG waveforms (10 s) on Fz and Pz scalp electrodes for Nold, ADD, PDD, and DLB subjects. 
These subjects were carefully selected to represent the general features of EEG 
waveforms in the groups of individuals investigated in the present study.  
Insert here Figure 1 
 
The rsEEG data were divided into segments of 2 seconds and analyzed off-line. The 
epochs affected by any physiological (ocular/blinking, muscular, head movements) or 
non-physiological (bad contact electrode-scalp) artifacts were preliminarily identified by 
an automatic computerized procedure (Moretti et al., 2003). Furthermore, two 
independent experimenters manually checked and (dis)confirmed the artifact-free rsEEG 
epochs, before successive analyses. Specifically, they controlled for the presence of ocular 
and blinking artifacts based on electro-oculographic signals, while muscular and head 
artifacts were recognized by analyzing EEG signals. Moreover, head artifacts were 
detected by a sudden and great increase in amplitude of slow EEG waves in all scalp 
electrodes. Finally, muscle artifacts were recognized observing the effects of several 
frequency bandpass filters in different ranges and by the inspection of EEG power density 
spectra. Muscle tension is related to unusually high and stable values of EEG power 
density from 30 to 100-150 Hz, which contrast with the typical declining trend of EEG 
power density from 25 Hz onward. As a result, the two experimenters selected 118 (± 5 
SE) artifact-free EEG epochs in the Nold group, 106 (± 7 SE) in the ADD group, 84 (± 5 SE) 
in the PDD group and 105 (± 5 SE) in the DLB group. The artifact-free epochs showed the 
same proportion of the total amount of rsEEG recorded in all groups (> 80%). 
A standard digital FFT-based power spectrum analysis (Welch technique, Hanning 
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windowing function, no phase shift) computed the power density of scalp rsEEG rhythms 
with 0.5 Hz of frequency resolution. The frequency bands of interest were individually 
identified based on the following frequency landmarks: the transition frequency (TF) and 
the IAF. In the EEG power density spectrum, the TF marked the transition frequency 
between the theta and alpha bands, defined as the minimum of the rsEEG power density 
between 3 and 8 Hz (between the delta and the alpha power peak). Instead, the IAF was 
defined as the maximum power density peak between 6 and 14 Hz. These frequency 
landmarks were originally introduced in the individual frequency analysis of EEG activity 
by Dr. Wolfgang Klimesch (Klimesch, 1996, 1999 and Klimesch et al., 1998). Of note, the 
relative individual frequency bands are useful to account for the “slowing” in frequency of 
rsEEG rhythms due to dementing disorders. However, they do not provide a clear cut 
threshold to discriminate a patient with a dementing disorder from an Nold individual 
with an innate slowing of that frequency in rsEEG rhythms. 
The TF and IAF were computed for each subject involved in the study. Based on 
the TF and IAF, we estimated the individual delta, theta, and alpha bands as follows: delta 
from TF -4 Hz to TF -2 Hz, theta from TF -2 Hz to TF, low-frequency alpha (alpha 1 and 
alpha 2) from TF to IAF, and high-frequency alpha (or alpha 3) from IAF to IAF + 2 Hz. 
Specifically, the individual alpha 1 and alpha 2 bands were computed as follows: alpha 1 
from TF to the frequency midpoint of the TF-IAF range and alpha 2 from that midpoint to 
IAF. The other bands were defined based on the standard fixed frequency ranges used in 
the reference study (Babiloni et al., 2017): beta 1 from 14 to 20 Hz, beta 2 from 20 to 30 
Hz, and gamma from 30 to 40 Hz. 
 
Estimation of functional connectivity of rsEEG cortical sources  
The eLORETA freeware was used to estimate the functional cortical connectivity 
from rsEEG rhythms (Pascual-Marqui, 2007a). Specifically, we used the toolbox called 
lagged linear connectivity (LLC; Pascual-Marqui et al., 2011). LLC provides linear 
measurements (from now on “LLC solutions”) of the statistical interdependence of pairs 
of eLORETA cortical source activations estimated from scalp rsEEG rhythms at a given 
frequency. The procedure provides LLC solutions between all combinations of voxels in 
the cortical source space of eLORETA (Pascual-Marqui et al., 2011). In its practical use, 
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researchers can average those LLC solutions across eLORETA voxels for pairs of regions of 
interest (ROIs).  
Noteworthy, LLC solutions are estimated by removing the zero-lag instantaneous 
phase interactions between rsEEG cortical sources estimated by eLORETA freeware. The 
rationale is that these zero-lag phase interactions could be affected by instantaneous 
physical propagation of neural ionic currents from a given source to all the others merely 
due to head volume conductor effects (Pascual-Marqui, 2007b). Furthermore, the LLC 
solutions took into account measures of interdependence among multivariate rsEEG time 
series, thus partially mitigating the head volume conduction component of the so-called 
“common drive/source” effect of a “third” source on the LLC solutions estimated between 
two sources of interest (Pascual-Marqui, 2007c). However, the LLC solutions are 
intrinsically “bivariate” measuremens that may not take into account for the “common 
drive/source” due to the propagation of actions potentials along nerves to two (or more) 
target cortical neural populations generating EEG signals. In the case of a “common 
drive/source”, the EEG signals generated from these target populations are expected to 
be delayed one in respect to another because of different axon path lengths. As a result, 
there may be phase differences between them accompanied with high coherence values 
not related to a “true” functional connection.  
For each subject and frequency band of interest (i.e. delta, theta, alpha 1, alpha 2, 
alpha 3, beta 1, beta 2, and gamma), LLC solutions were computed for 5 ROIs, namely 
frontal, central, parietal, occipital, and temporal lobes in the eLORETA cortical source 
space (Pascual-Marqui, 2007a).  
For the interhemispheric analysis, the LLC solutions were calculated between all 
voxels of the mentioned ROIs of each hemisphere with the homologous ones of the other 
hemisphere. The LLC solutions for all voxels of a given pair of ROIs were averaged. For 
each frequency band of interest, the following 5 interhemispheric LLC solutions were 
computed: frontal (i.e. frontal left - frontal right LLC), central (i.e. central left – central 
right LLC), parietal (i.e. parietal left - parietal right LLC), occipital (i.e. occipital left - 
occipital right LLC), and temporal (i.e. temporal left - temporal right LLC). 
For the intrahemispheric analysis, the LLC solutions were computed for all voxels 
of a particular ROI with all voxels of another ROI of the same hemisphere. The LLC 
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solutions for all voxels of a given pair of ROIs were averaged. This operation was repeated 
for the left and the right hemisphere, separately. In particular, for each frequency band of 
interest and the left hemisphere, the following 5 left intrahemispheric LLC solutions were 
computed: (1) frontal (i.e. mean among left frontal - central, left frontal - parietal, left 
frontal - temporal, and left frontal - occipital LLC), (2) central (i.e. mean among left central 
- frontal, left central - parietal, left central - temporal, and left central - occipital LLC), (3) 
parietal (i.e. mean among left parietal - frontal, left parietal - central, left parietal - 
temporal, and left parietal - occipital LLC), (4) occipital (i.e. mean among left occipital - 
frontal, left occipital - central, left occipital - parietal, and left occipital - temporal LLC), 
and 5) temporal (i.e. mean among left temporal - frontal, left temporal - central, left 
temporal - parietal , and left temporal - occipital LLC). The same procedure was repeated 
for the right hemisphere. 
Table 2 reports the Talairach coordinates of the centroid voxel for the left and 
right frontal, central, parietal, occipital, and temporal ROIs 
Insert here Table 2 
 
Statistical analysis of the LLC of rsEEG cortical sources 
The main statistical session was performed by the commercial tool STATISTICA 10 
(StatSoft Inc., www.statsoft.com) to test the hypothesis that the functional cortical 
connectivity as revealed by the eLORETA LLC solutions between rsEEG source pairs 
(hereinafter LLC solutions) might differ between the ADD, PDD, and DLB groups, using the 
Nold group as a control reference. To this aim, two ANOVAs were computed using the 
eLORETA LLC solutions as dependent variables (p < 0.05).  
The first ANOVA tested the differences of interhemispheric LLC solutions between 
the ADD, PDD, and DLB groups using the Nold group as a control reference. The ANOVA 
factors were Group (Nold, ADD, PDD, and DLB), Band (delta, theta, alpha 1, alpha 2, alpha 
3, beta 1, beta 2, and gamma), and ROI (frontal, central, parietal, occipital, and temporal). 
The second ANOVA also tested the differences of intrahemispheric LLC solutions 
between the ADD, PDD, and DLB groups using the Nold group as a control reference. The 
ANOVA factors were Group (Nold, ADD, PDD, and DLB), Hemisphere (left and right), Band 
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(delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, 
central, parietal, occipital, temporal, and limbic).   
Individual TF and the IAF values were used as covariates. Mauchly's test evaluated 
the sphericity assumption. The degrees of freedom were corrected by the Greenhouse-
Geisser procedure when appropriate (p < 0.05).  
Duncan test was used for post-hoc comparisons (p < 0.05). The planned post-hoc 
testing evaluated the primary hypothesis about the differences in the LLC solutions 
between the ADD, PDD, and DLB groups, using the Nold group as a control reference. 
Specifically, we tested the following predictions: (1) a statistically significant interaction 
effect including the factor Group (p < 0.05); (2) a post-hoc test indicating statistically 
significant differences in the LLC solutions between the ADD, PDD, DLB, and Nold groups 
(Duncan test, p < 0.05). The input data for the mentioned statistical analyses were 
controlled by the Grubbs test (p < 0.0001) for the presence of outliers in the distribution 
of the LLC solutions.  
As an exploratory statistical analysis at the individual level, Spearman test evaluated 
the correlation between the MMSE score and LLC solutions showing statistically 
significant differences between the Nold and the patients’ groups (p < 0.05). The 
correlation analysis was performed considering all Nold, ADD, PDD, and DLB individuals as 
a whole group for two reasons. On the one hand, the hypothesis was that LLC solutions 
from rsEEG cortical sources were correlated with the global cognitive status in seniors in 
general, namely including cases with both normal and impaired cognitive functions. On 
the other hand, the correlation study would have had a low statistical sensitivity if 
performed only in the separate groups, due to the very limited scatter of the MMSE 
scores within a given group (e.g. in Nold subjects, MMSE score can just assume discrete 
values of 30, 29, and 28). To take into account the inflating effects of repetitive univariate 
tests, the statistical threshold was determined based on the Bonferroni correction at p < 
0.05.  
 
Accuracy of the discrimination between the Nold, ADD, PDD, and DLB individuals based on 
eLORETA LLC solutions  
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eLORETA LLC solutions showing statistically significant differences (p < 0.05) 
among the four groups in the above ANOVAs (i.e. effects of the factor Group and Duncan 
post-hoc) were used as discriminant variables for the classification of the Nold subjects 
and the demented patients of each pathological group (i.e. Nold vs. ADD, Nold vs. DLB, 
and Nold vs. PDD) and between the patients of pairs of the pathological groups (i.e. ADD 
vs. DLB, ADD vs. PDD, and DLB vs. PDD). These classifications were performed by 
GraphPad Prism software (GraphPad Software, Inc., California, USA) using its 
implementation of ROC curves (DeLong et al., 1988). The following indexes measured the 
results of the binary classifications: (1) Sensitivity. It measures the rate of the cases (i.e. 
patients with dementia in the classifications of those patients and Nold subjects) who 
were correctly classified as cases (i.e. “true positive rate” in the signal detection theory); 
(2) Specificity. It measures the rate of the controls (i.e. Nold subjects in the classifications 
of those subjects and patients with dementia) who were correctly classified as controls 
(i.e. “true negative rate” in the signal detection theory); (3) Accuracy. It is the mean 
between the sensitivity and specificity weighted for the number of cases and controls; 
and (4) AUROC curve. For the sake of brevity, the AUROC curve was used as a major 
reference index of the global classification accuracy. 
 
Results 
Comparison of TF and IAF  
Table 3 reports the mean values of TF and IAF for the 4 groups (i.e., Nold, ADD, 
PDD, and DLB), together with the results of the statistical comparisons between the 
groups (ANOVA). The mean TF was 5.9 Hz (±0.2 SE) in the Nold, 5.4 Hz (±0.2 SE) in the 
ADD, 4.8 Hz (±0.1 SE) in the PDD, and 4.9 Hz (±0.1 SE) in the DLB group. The mean IAF was 
9.0 Hz (±0.2 SE) in the Nold, 8.0 Hz (±0.3 SE) in the ADD, 7.3 Hz (±0.2 SE) in the PDD, and 
7.2 Hz (±0.2 SE) in the DLB group.  
The statistical analysis of those values showed the following results. There was a 
main effect of the ANOVA using the TF as a dependent variable and the factor Group (F = 
10.4, p < 0.0001). Duncan post-hoc test showed that the mean TF was greater in the Nold 
than the ADD (p < 0.05), the PDD (p < 0.00001), and the group DLB (p < 0.00005). 
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Furthermore, the mean TF was higher in the ADD than the PDD (p < 0.05) and the DLB 
group (p < 0.05).  
Another result was the main effect of the ANOVA using the IAF as a dependent 
variable and the factor Group (F = 14.9, p < 0.00001). Duncan post-hoc test showed that 
the mean IAF was greater in the Nold than the ADD (p < 0.001), the PDD (p < 0.00001), 
and the DLB group (p < 0.000005). The mean IAF was also higher in the ADD than the PDD 
(p < 0.05) and the DLB group (p < 0.01).  
As a remark, 9 ADD, 2 PDD, and 5 DLB patients exhibited asymptotic rsEEG power spectra, 
without any alpha power peak. Therefore, they were not considered for the statistical 
analysis of IAF. For the analysis of LLC solutions, the frequency bands from delta to alpha 
were determined based on the group mean values of IAF. 
Insert Table 3 
 
Comparison of eLORETA interhemispheric LLC solutions  
Figure 2 shows mean values (± standard error mean, SE) of the interhemispheric LLC 
solutions relative to a statistically significant ANOVA interaction effect (F = 3.3, p < 
0.0001) among the factors Group (Nold, ADD, PDD, and DLB), Band (delta, theta, alpha 1, 
alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, central, parietal, occipital, 
and temporal). Here the LLC solutions reflect the statistical interdependence of pairs of 
homologous eLORETA cortical sources between the two hemispheres, estimated from 
scalp rsEEG rhythms at the frequency bands of interest. In Figure 2, the profile and 
magnitude of the interhemispheric LLC solutions clearly differed across the ROIs and 
frequency bands within and between the Nold, ADD, PDD, and DLB groups, exploiting 
spatial and frequency information contents of the methodological approach. 
 In the Nold group as a physiological reference, dominant values of 
interhemispheric LLC solutions were observed in temporal (maximum), occipital, and 
parietal alpha 2 and alpha 3 sources. Low values of interhemispheric LLC solutions were 
found in the widespread delta, theta, and alpha 1 sources. The LLC solutions in beta 1, 
beta 2, and gamma sources were close to zero, possibly confirming the lack of ocular, 
head, and muscular artefacts in the EEG data. Summarizing, the Nold group was 
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characterized by a prominent interhemispheric functional connectivity between posterior 
cortical sources from moderate to high-frequency alpha rhythms.  
Compared with the Nold group, the three patients’ groups (i.e. ADD, PDD, and 
DLB) showed a similar spatial and frequency profile of interhemispheric LLC solutions but 
a lower magnitude in the alpha range (beta 1, beta 2, and gamma sources were close to 
zero as in the Nold group). Specifically, there was a substantial decrease of the 
interhemispheric LLC solutions in parietal, occipital, and temporal alpha 2 and alpha 3 
sources, which was maximum in the ADD group. Furthermore, interhemispheric LLC 
solutions in delta sources generally showed a diffuse and very slight increase in the 
patients’ groups. The only exception was a more consistent increase of LLC solutions in 
delta sources in the ADD group.  
Duncan planned post-hoc testing revealed that the discriminant LLC pattern ADD < 
DLB < PDD < Nold was fitted only by the occipital and temporal alpha 3 sources (p < 0.05 
to 0.000001), which were decreased dramatically in the ADD group (p < 0.000001), 
markedly in the DLB group (p < 0.000001), and moderately in the PDD group (p < 0.005) 
compared with the Nold group. This interhemispheric effect was the most effective in 
differentiating the three neurodegenerative dementing disorders at the group level.   
Duncan planned post-hoc testing revealed that the discriminant LLC pattern ADD < 
DLB < PDD < Nold was fitted only by the occipital and temporal alpha 3 sources (p < 0.05 
to 0.000001), which were decreased dramatically in the ADD group (p < 0.000001), 
markedly in the DLB group (p < 0.000005), and moderately in the PDD group (p < 0.01) 
compared with the Nold group. This interhemispheric effect was the most effective in 
differentiating the three neurodegenerative dementing disorders at the group level.   
Another finding was the discriminant LLC pattern ADD < DLB and PDD < Nold, 
fitted only by the occipital and temporal alpha 2 sources (p < 0.005 to 0.000001). Those 
discriminant LLC solutions pointed to a dramatic reduction in the ADD group (p < 
0.000001) and a marked reduction in both DLB and PDD groups (p < 0.005) when 
compared to the Nold group. This interhemispheric effect was the most effective in 
differentiating ADD vs. DLB/PDD at the group level.   
The discriminant LLC pattern ADD and DLB < PDD < Nold was fitted only by the 
parietal alpha 2 and alpha 3 sources (p < 0.005 to 0.000005). Those discriminant LLC 
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solutions indicated a dramatic reduction in the ADD and DLB groups (p < 0.000005) and a 
marked reduction in the PDD group (p < 0.0001) in relation to the Nold group. This 
interhemispheric effect was the most effective in differentiating ADD/DLB vs. PDD at the 
group level. 
Finally, interhemispheric LLC solutions in delta sources showed only a unique 
effect in the occipital delta sources, namely greater solutions in the ADD than the Nold 
and PDD groups (p < 0.05).  
Insert here Figure 2 
 
Comparison of eLORETA intrahemispheric LLC solutions  
Figure 3 plots mean values (± SE) of the intrahemispheric LLC solutions relative to a 
statistically significant ANOVA interaction effect (F = 3.2, p < 0.0001) among the factors 
Group (Nold, ADD, PDD, and DLB), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, 
beta 2, and gamma), and ROI (frontal, central, parietal, occipital, and temporal). 
Noteworthy, there was no effect of the factor Hemisphere (left and right), pointing to a 
substantial symmetry of the intrahemispheric LLC solutions on the left and the right side. 
In Figure 3, the profile and magnitude of the intrahemispheric LLC solutions clearly 
differed across the ROIs and frequency bands within and between the Nold, ADD, PDD, 
and DLB groups.  
In the Nold group as a reference, dominant values of intrahemispheric LLC 
solutions were observed in temporal (maximum), occipital, and parietal alpha 2 and alpha 
3 sources, while moderate values were found in central and frontal alpha 2 and alpha 3 
sources. Low interhemispheric LLC solutions were found in the delta, theta, and alpha 1 
sources in all ROIs. As for the interhemispheric LCC solutions, the intrahemispheric LLC 
solutions in beta 1, beta 2, and gamma sources were close to zero, possibly confirming 
the lack of ocular, head, and muscular artefacts in the EEG data. On the whole, the Nold 
group was characterized by a prominent intrahemispheric functional connectivity in 
widespread cortical sources of moderate to high-frequency alpha rhythms. 
As for the intrahemispheric LLC solutions, the three patients’ groups (i.e. ADD, 
PDD, and DLB) showed a similar spatial and frequency profile of intrahemispheric LLC 
solutions but a lower magnitude in the alpha range (beta 1, beta 2, and gamma sources 
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were close to zero as in the Nold group). Specifically, there was a substantial decrease of 
the intrahemispheric LLC solutions in central, parietal, occipital, and temporal alpha 2 and 
alpha 3 sources, which was maximum in the ADD and DLB groups. Furthermore, 
intrahemispheric LLC solutions in delta sources generally showed a diffuse but slight 
increase in the patients’ groups. The only exception was a more consistent increase in 
those solutions in temporal, parietal, and occipital delta sources in the ADD group.  
In contrast to the interhemispheric LLC solutions, Duncan planned post-hoc testing 
revealed no significant discriminant LLC pattern ADD < DLB < PDD < Nold (p > 0.05) for the 
intrahemispheric LLC solutions, mostly due to the similar profiles of the latter in the ADD 
and DLB groups.    
An interesting finding was the discriminant LLC pattern ADD and DLB < PDD < Nold 
fitted by many sources, namely the central, parietal, temporal, and occipital alpha 2 and 
alpha 3 sources (p < 0.0005 to < 0.000001). These discriminant intrahemispheric LLC 
solutions showed a dramatic reduction in the ADD and DLB groups (p < 0.000001), while 
the decrease was moderate in the PDD group (p < 0.00005) as compared to the Nold 
group. This intrahemispheric effect was the most efficient in disentangling ADD/DLB and 
PDD at the group level. 
Another finding was the discriminant intrahemispheric LLC pattern ADD < DLB and 
PDD < Nold, fitted only by the frontal alpha 2 sources (p < 0.05 to 0.00001). These 
discriminant LLC solutions exhibited a very marked reduction in the ADD group (p < 
0.00001), while the decrease was moderate in the DLB and PDD groups (p < 0.05). This 
was the only intrahemispheric effect differentiating ADD and DLB at the group level. 
Finally, intrahemispheric LLC solutions in the temporal delta sources were higher 
in the ADD than the Nold, PDD, and DLB groups (p < 0.05 to 0.005). In addition, 
intrahemispheric LLC solutions in the frontal, central, parietal, and occipital delta sources 
were higher in the ADD than the Nold group (p < 0.01 to 0.0001). 
Insert here Figure 3 
 
A control statistical analysis was performed to verify that the above discriminant 
LLC solutions were not merely due to some outliers. To this aim, the Grubbs' test (p < 
0.0001) tested the presence of outliers in the data of the four groups (i.e. Nold, ADD, DLB, 
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and PDD). The analysis was performed for the 6 discriminant interhemispheric LLC 
solutions in the alpha sources (i.e. parietal, occipital, and temporal alpha 2; parietal, 
occipital, and temporal alpha 3) and the 9 discriminant intrahemispheric LLC solutions in 
those sources (i.e. frontal, central, parietal, occipital, and temporal alpha 2; central, 
parietal, occipital, and temporal alpha 3). Furthermore, this analysis was also performed 
for 1 interhemispheric LLC solution in the occipital delta sources and 5 intrahemispheric 
LLC solutions in the frontal, central, parietal, occipital, and temporal delta sources. No 
outlier was found in any group (see Figure 4 and Figure 5), thus confirming the results of 
the main statistical analysis.  
Insert here Figure 4 and Figure 5 
 
Correlation of LLC solutions and MMSE scores across Nold, ADD, DLB, and PDD individuals  
As a first exploratory analysis at the individual level, Spearman test evaluated the 
correlation between the MMSE score, and 21 LLC solutions showing statistically 
significant differences between the Nold and the patients’ groups (p < 0.05). These LLC 
solutions are listed in the following: (1) interhemispheric LLC solutions in the occipital 
delta sources; (2) interhemispheric LLC solutions in the parietal, occipital, and temporal 
alpha 2 sources; (3) interhemispheric LLC solutions in the parietal, occipital, and temporal 
alpha 3 sources; (4) intrahemispheric LLC solutions in the frontal, central, parietal, 
occipital, and temporal delta sources; (5) intrahemispheric LLC solutions in the frontal, 
central, parietal, occipital, and temporal alpha 2 sources; and (6) intrahemispheric LLC 
solutions in the central, parietal, occipital, and temporal alpha 3 sources. To take into 
account the inflating effects of repetitive univariate tests, the statistical threshold was set 
at p < 0.0023 to obtain the Bonferroni correction at p < 0.05.  
A positive correlation was found between the interhemispheric LLC solutions in the 
temporal alpha 3 sources and the MMSE scores (r = 0.24, p < 0.002). The lower the 
interhemispheric LLC solutions, the lower the MMSE score. Similarly, the intrahemispheric 
LLC solutions in the central (r = 0.26, p < 0.001), parietal (r = 0.26, p < 0.001), and occipital 
(r = 0.26, p < 0.002) alpha 3 sources were correlated with the MMSE scores. The lower the 
intrahemispheric LLC solutions, the lower the MMSE scores. Figure 6 shows the 
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scatterplots of those 4 LLC solutions showing statistically significant correlations (p < 0.05 
corrected).  
The LCC solutions in the delta sources showed only marginal statistical effects. 
There was a significant negative correlation between the interhemispheric occipital delta 
sources and the MMSE score (r = -0.21; p = 0.005). The higher the interhemispheric LLC 
solutions in those sources, the lower the MMSE score.  
As a control analysis, the same correlation test was performed for any single group 
considered separately. No statistically significant result (p > 0.05) was observed, possibly 
due to the limited range of the MMSE score within the single groups. 
Insert here Figure 6 
 
Classification among Nold, ADD, PDD, and DLB individuals based on the discriminant LLC 
solutions  
As a second exploratory analysis at the individual level, the above 15 LLC solutions 
showing statistically significant differences between the Nold and the three patients’ 
groups (p < 0.05) were used as an input to the computation of the AUROC curves. 
Additionally, this analysis was also performed for 1 interhemispheric LLC solution in the 
occipital delta sources and 5 intrahemispheric LLC solutions in the frontal, central, 
parietal, occipital, and temporal delta sources for the classification of the Nold and ADD 
individuals. This second exploratory analysis tested the ability of those LLC solutions in the 
classification of (1) Nold subjects vs. patients and (2) patients of two paired pathological 
groups (i.e. ADD vs. DLB, ADD vs. PDD, DLB vs. PDD).  Maximum classification accuracies 
were obtained in the classification between the Nold subjects and ADD patients and 
between the Nold and DLB patients. Table 4 reports the results in detail.  
The classification between Nold vs. ADD individuals showed that all 15 LLC solutions 
in the alpha sources overcome the threshold of 0.7 of the AUROC curve (i.e. the inferior 
limit of a “moderate” classification rate). Among these LLC solutions, the interhemispheric 
temporal alpha 3 LLC solutions reached the following best classification rate (Figure 7 
top): a sensitivity of 78.6%, a specificity of 77.5%, an accuracy of 78.1%, and 0.84 of the 
AUROC curve. Among the LLC solutions of the delta sources, the only interhemispheric 
occipital delta LLC solutions reached the threshold of 0.7 of the AUROC curve. It was 
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observed a sensitivity of 61.9%, a specificity of 77.5%, an accuracy of 69.8%, and 0.70 of 
the AUROC curve. 
Concerning the classification of the Nold vs. PDD individuals, only the following 2 
LLC solutions in alpha sources overcome the threshold of 0.7 of the AUROC curve (Table 
4): interhemispheric LLC solutions in the temporal alpha 2 and alpha 3 sources. Among 
these LLC solutions, the interhemispheric LLC solutions in the temporal alpha 2 sources 
reached the following best classification rate (Figure 7, middle): a sensitivity of 82.3%, a 
specificity of 70%, an accuracy of 76.2%, and 0.75 of the AUROC curve. 
Regarding the classification of the Nold vs. DLB individuals, the following 12 LLC 
solutions in alpha sources overcome the threshold of 0.7 of the AUROC curve (Table 4): 
(1) interhemispheric LLC solutions in the parietal alpha 2, temporal alpha 2, parietal alpha 
3, and temporal alpha 3 sources and (2) intrahemispheric LLC solutions in the central 
alpha 2, parietal alpha 3, temporal alpha 2, occipital alpha 2, central alpha 3, parietal 
alpha 3, occipital alpha 3, and temporal alpha 3 sources. Among these LLC solutions, the 
intrahemispheric 2 LLC solutions in the central alpha sources reached the following best 
classification rate (Figure 7, bottom): a sensitivity of 83.5%, a specificity of 65%, an 
accuracy of 74.3%, and 0.78 of the AUROC curve. 
Insert here Figure 7 and Table 4 
Control analysis 
As mentioned above, head volume condution and “common drive/source” on EEG 
signals may mislead estimates (especially “bivariate”) of functional connectivity inducing a 
number of “false” connections between pairs of scalp sensors or source solutions. Typically, 
these “false” connections are characterized by a “random” spatial topology. Keeping in mind 
the considerations, we performed a control analysis focused on the alpha souces (a relevant 
EEG frequency band in the present study) aimed at testing the hypotheses that 1) the 
present LLC solutions did not show a “random” spatial scheme between the pairs of ROIs in 
the Nold group and 2) the statistical differences in the alpha LLC solutions between the Nold 
group and the ADD, PDD or DLB group did not show a “random” spatial scheme between 
the ROI pairs. To test these hypotheses, we used the following ANOVA designs with LLC 
solutions between pairs of ROIs as a dependent variable. The post-hoc analysis compared 
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the LLC solutions for between the pairs of ROIS using a liberal threshold of p < 0.05 allowing 
a “random” topology of the functional connections to emerge, if present. 
The first control ANOVA design was focused on the alpha LLC solutions of the Nold 
group (p < 0.05). The ANOVA factors were Band (alpha 2 and alpha 3) and Pair of ROIs 
(frontal-central, frontal-temporal, central-temporal, frontal-parietal, central-parietal, 
temporal-parietal, frontal-occipital, central-occipital, temporal-occipital, and parietal-
occipital). The results showed a significant main effect for the factor Pair of ROIs (F = 35.9, p 
< 0.00001), regardless the alpha sub-bands. The Duncan post-hoc analysis showed a 
characteristic topology of the pairs of ROIs exhibiting the greatest effects. For example, the 
parietal-occipital alpha LLC solutions were higher than those in the temporal-occipital (p < 
0.00001), temporal-parietal (p < 0.00005), central-parietal (p < 0.00001), central-temporal (p 
< 0.00001), frontal-temporal (p < 0.00001), and frontal-central (p < 0.00001), despite a 
similar spatial distance between the ROIs in those pairs. In the same line, the temporal-
parietal alpha LLC solutions were higher than those in the frontal-temporal (p < 0.00001) 
and frontal-central (p < 0.00001), despite a similar spatial distance between the ROIs in 
those pairs. The Figure 8 (A) and Table 5 report all details of the results of the first control 
ANOVA design.  These results are not in line with a “random” topology of the functional 
connections.  
The second control ANOVA design was focused on the alpha LLC solutions in the 
comparison between the Nold and the ADD group (p < 0.05). The ANOVA factors were 
Group (Nold and ADD),  Band (alpha 2 and alpha 3), and Pair of ROIs (frontal-central, frontal-
temporal, central-temporal, frontal-parietal, central-parietal, temporal-parietal, frontal-
occipital, central-occipital, temporal-occipital, and parietal-occipital). The results showed a 
significant Interaction Group X Pair of ROIs (F = 5.7, p < 0.00001), regardless the alpha sub-
bands. The Duncan post-hoc analysis showed a characteristic topology of the pairs of ROIs 
having the highest values of alpha LLC solutions in the ADD group. For example, the parietal-
occipital alpha LLC solutions were higher than those in the frontal-central (p < 0.00001) and 
central-temporal (p < 0.0001) pairs of ROIs, despite a similar spatial distance between the 
ROIs in those pairs. The Duncan post-hoc analysis also showed the pairs of ROIs exhibiting 
the significant differences in the alpha LLC solutions between the Nold and the ADD group. 
Compared to the Nold group, the ADD group showed lower alpha LLC solutions in frontal-
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temporal, central-temporal, central-parietal, temporal-parietal, central-occipital, temporal-
occipital, and parietal-occipital pairs of ROIs (p < 0.005 to 0.000001). Among them, a clear 
topology emerged. For example, the differences were higher in the parietal-occipital (p < 
0.00001) than the temporal-parietal (p < 0.0005), temporo-occipital (p < 0.001),  frontal-
temporal (p < 0.005), and frontal-central (n.s.) pairs of ROIs. The Figure 8 (B) report all 
details of the results of the second control ANOVA design. These results are not in line with 
a “random” topology of the differences in the functional connections between the Nold and 
the ADD group. 
The third control ANOVA design was focused on the alpha LLC solutions in the 
comparison between the Nold and the PDD group (p < 0.05). The ANOVA factors were 
Group (Nold and PDD),  Band (alpha 2 and alpha 3), and Pair of ROIs (frontal-central, frontal-
temporal, central-temporal, frontal-parietal, central-parietal, temporal-parietal, frontal-
occipital, central-occipital, temporal-occipital, and parietal-occipital). The results showed a 
significant Interaction Group X Pair of ROIs (F = 2.5, p < 0.01), regardless the alpha sub-
bands. The Duncan post-hoc analysis showed a characteristic topology of the pairs of ROIs 
having the highest values of alpha LLC solutions in the PDD group. For example, the parietal-
occipital alpha LLC solutions were higher than those in the parietal-temporal (p < 0.01) pairs 
of ROIs, despite a similar spatial distance between the ROIs in those pairs. In the same line, 
the central-parietal alpha LLC solutions were higher than those in the frontal-central (p < 
0.00001) and frontal-parietal (p < 0.00001) pairs of ROIs. The Duncan post-hoc analysis also 
showed a characteristic topology of the pairs of ROIs exhibiting the significant differences in 
the alpha LLC solutions between the Nold and the PDD group (p < 0.05). Compared to the 
Nold group, the PDD group showed lower alpha LLC solutions only in the central-temporal, 
central-parietal, temporal-parietal, and parietal-occipital pairs of ROIs (p < 0.05 to 0.00001). 
The Figure 8 (C) report all details of the results of the third control ANOVA design. These 
results are not in line with a “random” topology of the differences in the functional 
connections between the Nold and the PDD group. 
The fourth control ANOVA design was focused on the alpha LLC solutions in the 
comparison between the Nold and the DLB group (p < 0.05). The ANOVA factors were Group 
(Nold and DLB),  Band (alpha 2 and alpha 3), and Pair of ROIs (frontal-central, frontal-
temporal, central-temporal, frontal-parietal, central-parietal, temporal-parietal, frontal-
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occipital, central-occipital, temporal-occipital, and parietal-occipital). The results showed a 
significant Interaction Group X Pair of ROIs (F = 4.2, p < 0.00005), regardless the alpha sub-
bands. The Duncan post-hoc analysis showed a characteristic topology of the pairs of ROIs 
having the highest values of alpha LLC solutions in the DLB group. For example, the parietal-
occipital alpha LLC solutions were higher than those in the central-temporal (p < 0.001), and 
frontal-central (p < 0.0005) pairs of ROIs, despite a similar spatial distance between the ROIs 
in those pairs. The Duncan post-hoc analysis also showed a characteristic topology of the 
pairs of ROIs exhibiting the significant differences in the alpha LLC solutions between the 
Nold and the DLB group (p < 0.05). Compared to the Nold group, the DLB group showed 
lower alpha LLC solutions in the central-temporal, central-parietal, temporal-parietal, 
central-occipital, temporal-occipital, and parietal-occipital (p < 0.005 to 0.000001). Among 
them, a clear topology emerged. For example, the differences were higher in the parietal-
occipital (p < 0.000001) than the temporal-parietal (p < 0.00001),  temporo-occipital (p < 
0.005), frontal-central (n.s.), and frontal-temporal (n.s.) pairs of ROIs, despite a similar 
spatial distance between the ROIs in those pairs. The Figure 8 (D) report all details of the 
results of the third control ANOVA design. These results are not in line with a “random” 
topology of the differences in the functional connections between the Nold and the DLB 
group. 
Insert here Figure 8 and Table 5 
 
Discussion 
In the present exploratory investigation, we re-analyzed the rsEEG data of a 
previous reference study (Babiloni et al., 2017) to test the core hypothesis that ADD 
patients might show the maximum abnormality of “functional cortical connectivity” 
compared with DLB and PDD patients, leading support to the idea of AD as a “cortical 
disconnection syndrome”, Intrahemisphericly and Interhemisphericly (Besthorn et al., 
1994; Bokde et al., 2009; Dunkin et al., 1995; Leuchter et al., 1994; Reuter-Lorenz and 
Mikels, 2005; Teipel et al., 2016). The data re-analysis was performed computing the 
interhemispheric and intrahemispheric (eLORETA) LLC solutions in cortical sources of 
rsEEG rhythms at individually-selected frequency bands. The results are summarized and 
discussed in the following sections. 
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The functional cortical connectivity in alpha sources was maximally abnormal in the AD 
group  
In the Nold group as a physiological reference, interhemispheric and 
intrahemispheric LLC solutions were dominant in posterior alpha sources, suggesting a 
possible strict relationship of this extensive posterior functional connectivity with the 
prominent local activation of the same alpha sources, previously reported from the same 
database (Babiloni et al., 2017). Compared to the Nold group, the decrement of LLC 
solutions in alpha sources was dramatic in the ADD group, marked in the DLB group, and 
moderate in the PDD group. Furthermore, he intrahemispheric LLC solutions in 
widespread alpha sources exhibited a greater reduction in both ADD and DLB groups 
when compared to the PDD group. Finally, the LLC solutions in frontal alpha sources 
pointed to a very marked reduction in the ADD group compared with the moderate 
decrease found in both DLB and PDD groups.  
On one hand, these findings might reflect similarities and differences in cortical 
neuropathology and clinical features among ADD, DLB, and PDD. This similarity was 
observed between ADD and DLB in a recent retrospective study based on data from 213 
patients receiving a diagnosis of LBD and α synucleinopathy confirmed by brain autopsy 
(Irwin et al., 2017).  There were 23% patients with no AD neuropathology, 26% with low-
level AD neuropathology, 21% with intermediate-level AD neuropathology, and 30% with 
high-level AD neuropathology (Irwin et al., 2017). Furthermore, the increased AD 
neuropathology was associated with higher cerebral α-synuclein scores and a shorter 
interval between the onset of motor or dementia symptoms and the death (Irwin et al., 
2017). In another study, about 25% of DLB patients and 9% of PDD patients had abnormal 
CSF values for t-tau, Aβ42, and p-tau, thus suggesting that a CSF profile of AD is 
more common in DLB compared with PDD patients (van Steenoven et al., 2016). 
Moreover, there was evidence that compared with DLB patients with AD neuropathology, 
DLB patients without AD neuropathology showed greater impairment on visuospatial 
constructions, visual conceptual reasoning, the speed of processing, and more frequent 
hallucinations, but less impairment of confrontation naming and verbal memory (Peavy et 
al., 2016). Finally, compared with DLB patients negative to pathophysiological Aβ42 and 
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tau markers in CSF, DLB patients positive to those markers showed a greater decline in 
the MMSE score (Abdelnour et al., 2016). 
The present evidence of a common frontal effect in the DLB and PDD groups might 
be explained by the partially common neuropathology of subcortical projection to the 
frontal lobe and similar clinical features in the two diseases (Barker and Williams-Gray, 
2016). Both neurodegenerative dementing disorders share characteristic 
neuropathological changes including deposition of α-synuclein in Lewy bodies and 
neurites, loss of tegmental dopamine cell populations, loss of basal forebrain cholinergic 
projection to the cortex, and a variable degree of coexisting AD neuropathology (Irwin et 
al., 2017). Clinical constellations of both DLB and PDD include progressive cognitive 
impairment associated with parkinsonism, visual hallucinations, frontal executive 
dysfunctions, and fluctuations of attention and wakefulness (Barker and Williams-Gray, 
2016).  
The present results extend to source space and individually-determined frequency 
bands previous EEG evidence showing differences in the functional cortical connectivity 
estimated from scalp rsEEG rhythms in ADD, PDD, and DLB groups compared with Nold 
subjects (Adler et al., 2003; Andersson et al., 2008; Anghinah et al., 2000; Besthorn et al., 
1994; Dunkin et al., 1994; Fonseca et al., 2011, 2013; Jelic et al., 1997, 2000; Knott et al., 
2000; Leuchter et al., 1987, 1992; Locatelli et al., 1998; Moazami-Goudarzi et al., 2008; 
Pogarell et al., 2005; Sloan et al., 1994; van Dellen et al., 2015). In previous studies, ADD 
patients were characterized by lower functional cortical connectivity computed from 
posterior alpha (8-12 Hz) and beta (13-20 Hz) rhythms but the topographical regional 
localization of the effects was not consistent across the investigations with the exception 
of a prominent anterior-posterior axis of the connectivity alteration (Adler et al., 2003; 
Anghinah et al., 2000; Babiloni et al., 2004, 2006b, 2016b; Besthorn et al., 1994; 
Blinowska et al., 2017; Dunkin et al., 1994; Fonseca et al., 2011, 2013; Jelic et al., 1997, 
2000; Knott et al., 2000; Leuchter et al., 1987, 1992; Locatelli et al., 1998; Pogarell et al., 
2005; Sloan et al., 1994). Similarly, the present results extend as spatial and frequency 
specifications the previous evidence of abnormalities of the interhemispheric and 
intrahemispheric scalp frontoparietal alpha coherences in PD patients with cognitive 
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deficits (Fonseca et al., 2013; Teramoto et al., 2016) and DLB subjects (Dauwan et al., 
2016a).  
Previous investigations in animals have delineated an interesting model of the 
generation of cortical alpha rhythms in quiet wakefulness (Hughes & Crunelli, 2005; 
Lörincz et al., 2008, 2009). These rhythms might result from a physiological 
neurotransmission between populations of cortical pyramidal, thalamocortical, and 
reticular thalamic neurons (Hughes & Crunelli, 2005; Lörincz et al., 2008, 2009). Alpha 
rhythms in that thalamocortical network may produce cycles of neuronal excitation and 
inhibition that might frame perceptual events in discrete snapshots of around 70–100 ms 
during active sensory and motor information processing (Hughes & Crunelli, 2005; Lörincz 
et al., 2008, 2009). In this line, the present evidence of reduced alpha source connectivity 
in patients with dementia -especially in ADD subjects- might be due to a downregulation 
of that neurophysiological mechanism. As a result, an unselective tonic cortical excitation 
might occur in quiet wakefulness. Such cortical over excitation could represent a sort of 
background noise, possibly interfering with the switch of the cerebral cortex from quiet 
wakefulness to focused attention and local adaptive encoding and retrieval information 
processing when required by endogenous or external demands (Babiloni et al., 2016a).  
 
The functional cortical connectivity in delta sources was abnormal only in the AD group  
Here we report the negligible magnitude of the interhemispheric and 
intrahemispheric LLC solutions in delta sources estimated in the Nold group and the 
abnormal increase only in the ADD group. Specifically, the interhemispheric LLC solutions 
in the occipital delta sources were higher in the ADD than the Nold and PDD groups. 
Furthermore, the intrahemispheric LLC solutions in distributed delta sources were greater 
in the ADD than the Nold group, while those LLC solutions in temporal delta sources were 
higher in the ADD than the Nold, PDD, and DLB groups.  
The fact that delta source connectivity was abnormal in the ADD group but not the 
DLB and PDD groups was surprising as the delta sources of rsEEG rhythms were more 
abnormal in the same DLB and PDD patients compared with the AD ones in our previous 
reference study (Babiloni et al., 2017). We discussed this surprising dissociation of delta 
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source “synchronization/desynchronization” and “functional cortical connectivity” in a 
subsequent paragraph.  
The present findings agree with a previous study comparing LLC solutions in delta 
sources between Nold and ADD individuals (Babiloni et al., 2016a). Furthermore, they 
enrich with spatial details and individual frequency bands previous evidence showing 
differences in functional connectivity measurements from delta rhythms at scalp sensors 
between Nold and ADD individuals (Adler et al., 2003; Blinowska et al., 2017; Knott et al., 
2000; Locatelli et al., 1998; Sankari et al., 2011;).  
The present evidence of normal delta LLC solutions in DLB and PDD patients 
contrasts previous findings showing lower (Andersson et al., 2008; van Dellen et al., 2015) 
or higher (Kai et al., 2005; van Dellen et al., 2015) delta connectivity in DLB compared 
with ADD patients. At the present early stage of the research, we cannot give a final 
explanation for these discrepancies. It is unclear if they depend on (1) the current 
technique of multivariate LLC rather than bivariate coherence for the estimation of the 
rsEEG functional interdependence, (2) the computation of the functional connectivity at 
the cortical source rather than the scalp sensor level (e.g. LLC solutions in the source 
space and spectral coherence computed between scalp electrode pairs may be differently 
affected by residual ocular or muscular artifacts in the EEG signals), and (3) the use of 
individual rather than fixed frequency bands for the analysis of delta rhythms. Future 
studies should vary the mentioned methodological options systematically in the same 
database to clarify the matter.  
The neurophysiological mechanism generating human delta rhythms in quiet 
wakefulness is poorly known. A speculative explanation is that normal delta rhythms in 
quiet wakefulness are generated by intrinsic thalamocortical interactions associated with a 
relative functional isolation of cortical modules from the sensory flow, analogously to the 
neurophysiological mechanism producing slow waves in non-REM sleep (Crunelli et al., 
2015). Another speculative explanation is that the generating mechanism might be the 
“stand-by” mode of selective circuits of corticothalamic and relay thalamocortical neurons 
engaged in a fast information processing during cognitive tasks (Taylor et al., 2014).  
In the above theoretical framework, it can be just speculated that the present 
evidence of an abnormal posterior delta source connectivity in the ADD patients might 
32 
 
reflect an abnormal upregulation of the mechanisms generating normal delta rhythms in 
quiet wakefulness. In ADD patients, that upregulation might result from cortical blood 
hypoperfusion and synaptic dysfunction in the same regions (Niedermeyer et al., 1997; 
Passero et al., 1995; Rodriguez et al., 1999; Valladares-Neto et al., 1995). Other causes 
might be a white matter lesion (Agosta et al., 2013, 2014) or the loss of neurons in the 
cortical gray matter, especially in the posterior cortex (Babiloni et al., 2013, 2015b; Delli 
Pizzi et al., 2014, 2015, 2016; Fernandez et al., 2003; Graff-Radford et al., 2016; Sarro et al., 
2016).  
 
The LLC solutions in delta and alpha sources classified Nold vs. patients with dementia 
Here we report the results of two exploratory analyses aimed at testing the 
clinically relevance of the present findings. The first analysis showed significant positive 
correlations between MMSE scores (roughly reflecting global cognitive status) and LLC 
solutions in interhemispheric temporal and intrahemispheric diffuse alpha sources across 
all Nold, ADD, DLB, and PDD individuals as a whole group. However, even if statistically 
significant (p < 0.005), the correlation values were relatively low as variance explained 
(i.e. r = 0.24–0.26). Furthermore, no statistically significant correlation (p > 0.05) was 
observed for any single group considered separately. The present findings suggest that 
neurophysiological mechanisms of the interdependence of cortical neural 
synchronization/desynchronization underpinning brain arousal and low vigilance (as 
reflected in the LLC solutions of this study) are only one of the determinants of global 
cognitive functions in human subjects. Other relevant neurophysiological mechanisms 
involved in cognitive information processes may be those related to selective attention, 
encoding and retrieval of information in long-term memory, frontal executive functions 
(some assisted by internal language), and others. Therefore, future studies may measure 
functional connectivity not only during the resting state condition (i.e. low vigilance) but 
also during attention, episodic and working memory, and other cognitive tasks. The 
derived EEG markers may be used as a multivariate input for linear (logistics regression) 
and non-linear (artificial neural networks or support vector machines) predictors of the 
MMSE score in Nold subjects and patients with dementing disorders. The expected results 
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may show high correlation values and remarkable insights about the derangement of 
brain functions in the evolution of dementing disorders. 
The second analysis pointed to a moderate classification accuracy of several alpha 
LLC solutions in the discrimination of ADD vs. Nold, DLB, and PPD individuals. Specifically, 
interhemispheric LLC solutions in the temporal alpha sources showed an AUROC curve of 
0.84 vs. Nold individuals and 0.75 vs. DLB individuals while intrahemispheric LLC solutions 
in the central alpha sources exhibited an AUROC curve of 0.78 vs. PDD individuals. 
Noteworthy, the only substantial classification accuracy of the LLC solutions in delta 
sources was obtained with the interhemispheric LLC solutions in occipital delta sources 
discriminating Nold subjects vs. ADD patients (e.g. AUROC curve of 0.7). 
The present findings are in line with previous evidence showing the following 
values of classification accuracy (1) 1.0–0.45 for Nold vs. ADD individuals (e.g. 1 = 100%); 
(2) 0.92–0.78 for MCI vs. ADD individuals; and (3) 0.87–0.60 for the conversion from MCI 
to ADD status (Adler et al., 2003; Babiloni et al., 2015b, 2016b; Bennys et al., 2001; 
Blinowska et al., 2017; Brassen et al., 2004; Buscema et al., 2007; Claus et al., 1999; 
Engedal et al., 2015; Garn et al., 2017; Huang et al., 2000; Jelic et al., 2000; Knyazeva et 
al., 2010; Lehmann et al., 2007; Lizio et al., 2016; Missonnier et al., 2006; Nuwer, 1997).  
Concerning the classification of Nold vs. DLB and PDD individuals, the present 
discrimination with 0.75-0.78 of success was intermediate when compared with those 
reported in previous studies. In those investigations, global delta and alpha coherences 
between electrode pairs allowed a classification accuracy of 0.75-0.80 of DLB individuals 
compared with Nold subjects (Andersson et al., 2008). Another study (Roks et al., 2008) 
used grand total EEG score to discriminate DLB vs. Nold individuals with an accuracy of 
0.78. Finally, two advanced procedures using a combination of 20-25 discriminant rsEEG 
power density and connectivity measurements showed a classification accuracy of 0.80-
1.0 between PDD/DLB and Nold individuals (Engedal et al., 2015; Garn et al., 2017; 
Snaedal et al., 2012). Noteworthy, no previous cross-validated comparisons showed the 
ability of rsEEG markers in the discrimination of PDD vs. DLB patients to delineate the 
bounds between these entities at the individual level. 
 
The clinical neurophysiological model 
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In the reference study carried out in the same populations of the present 
investigation (Babiloni et al., 2017), rsEEG markers of 
“synchronization/desynchronization” were investigated. Results of that previous study 
suggest that posterior alpha source synchronization reduced dramatically in the ADD 
group, markedly in the DLB group, and moderately in the PDD group. In contrast, 
posterior delta source synchronization increased dramatically in the PDD group, markedly 
in the DLB group, and moderately in the ADD group. Compared to those findings, the 
present markers of “functional cortical connectivity” suggest maximum abnormalities of 
both delta and alpha source connectivity in the ADD group compared to the DLB and PDD 
groups, thus confirming the working hypothesis of this study. Interestingly, the present 
markers of “functional cortical connectivity” also suggest more abnormalities of alpha 
source connectivity in the DLB group compared to the PDD group.  
Keeping in mind these findings, two main considerations can be done. The first 
consideration is that the markers of the neurophysiological reserve lead support to the 
concept of ADD as “cortical disconnection syndrome.” The second consideration is that 
the combination of the markers of “synchronization/desynchronization” and “functional 
cortical connectivity” might enrich the assessment of cholinergic and dopaminergic 
neurotransmission in ADD, DLB, and PDD.  
Based on the present results and those of Babiloni and colleagues (2017), the 
distinguishing markers of the neurophysiological reserve in ADD patients might be a 
dramatic decrease of both “synchronization/desynchronization” and “functional cortical 
connectivity” in posterior alpha sources. Furthermore, these patients might show an 
increase of both those markers in posterior delta sources.  
In contrast, the distinguishing markers of the neurophysiological reserve in PDD 
and DLB patients might be a dissociation of “synchronization/desynchronization” and 
“functional cortical connectivity” markers in posterior delta sources, namely a marked 
increase of the former without a related increase of the latter.  
In this framework, ADD patients exhibited more similarities to DLB than PDD 
patients for both markers of “synchronization” and “functional cortical connectivity” in 
alpha and delta sources.  
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An exciting hypothesis for future studies is that those markers of the 
neurophysiological reserve might reflect cholinergic dysfunction in the ADD, cholinergic 
and dopaminergic dysfunction in DLB, and dopaminergic dysfunction in the PDD. Those 
studies should correlate the hypothesized rsEEG markers of cholinergic and/or 
dopaminergic dysfunction and relevant PET readouts of dopaminergic and cholinergic 
uptake in the brain. More questionable may be the acute use of scopolamine and 
risperidone in ADD, DLB, and PDD patients for the risk of clinical side effects. Overall, the 
evaluation of that clinical neurophysiological model is motivated by some encouraging 
previous evidence reported in the following paragraphs.  
Previous studies have unveiled a relationship between resting state delta and 
alpha rhythms and cholinergic neurotransmission in ADD patients. Indeed, it has been 
shown that AChEI drugs (i.e. enhancing the cholinergic tone) exerted beneficial effects on 
some rsEEG frequency bands, namely decreasing delta (Adler and Brassen, 2001; Balkan 
et al., 2003; Gianotti et al., 2008; Reeves et al., 2002) and theta (Adler et al., 2004; 
Brassen and Adler, 2003; Gianotti et al., 2008) while increased alpha power density 
(Agnoli et al., 1983; Babiloni et al., 2006c; Balkan et al., 2003).  
In healthy subjects, an acute dose of scopolamine (i.e. a muscarinic cholinergic 
antagonist) compared with placebo transiently increased delta and theta power density 
while reduced alpha and beta power density, in the way typically found in ADD patients 
(Ebert and Kirch, 1998). In addition, the scopolamine increased delta and reduced alpha 
power density in relation to plasma drug concentration and transient psychomotor 
impairment (Liem-Moolenaar et al., 2011a). 
In both Nold and ADD patients, the acute scopolamine intervention induced 
decreased alpha power density and increased delta power density, the drop in the Nold 
subjects being stronger as expected by the integrity of their cholinergic neurotransmission 
(Neufeld et al., 1994). More recently, an acute dose of scopolamine produced deranging 
effects on composite measurements of power density and coherence of delta, theta, 
alpha, beta, and gamma that had been successfully used to classify Nold and ADD 
individuals (Johannsson et al., 2015; Snaedal et al., 2010). 
Unfortunately, less clear is the relationship between the mentioned rsEEG markers 
in delta sources and dopaminergic neurotransmission in PDD and DLB patients. Some 
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previous studies provided support to the hypothesized relationship. Compared with Nold 
subjects, PD patients showed higher delta and theta power density in several scalp 
regions, more evident in association with a progressive cognitive impairment (Bonanni et 
al., 2008; Caviness et al., 2007; Morita et al., 2009, 2011; Pugnetti et al., 2010). 
Furthermore, these features appeared to be specific, as delta and theta power density 
values were higher in PDD patients than in ADD, PD, and Nold subjects (Babiloni et al. 
2011; Fonseca et al., 2013). Moreover, these features were specifically related to 
phosphorylation of α-synuclein in the posterior cingulate cortex (hub of the default mode 
network), namely the higher the α-synuclein load, the higher the global delta, the lower 
the global alpha power density, and the lower the frequency alpha peak (Caviness et al., 
2016).  
In the same line, global delta and theta power density and variability were higher 
in DLB than ADD patients (Andersson et al., 2008; Kai et al., 2005). The global delta power 
density fluctuated more in DLB than ADD patients within 1 hour of rsEEG recording 
(Andersson et al. 2008; Walker et al., 2000a, b).  
In healthy subjects, an acute dose of risperidone (i.e. an atypical antipsychotic 
dopamine and serotoninergic antagonist) compared with placebo transiently increased 
delta and/or theta power density of rsEEG rhythms in relation to plasma drug 
concentration (Lee et al., 1999) and transient psychomotor impairment (Hughes et al., 
1999; Liem-Moolenaar et al., 2011b).  
Noteworthy, other studies challenge the specificity of the relationship between 
the mentioned rsEEG markers in delta sources and dopaminergic neurotransmission in 
PDD and DLB patients. It was reported that treatment with AChEI (i.e. donepezil) partially 
normalized delta and theta power density (but not alpha) in DLB patients, while there was 
no significant difference in ADD patients. (Kai et al., 2005). Furthermore, L-DOPA and 
electrical stimulation of subthalamic nucleus enhancing the dopaminergic tone reduced 
intrahemispheric frontoparietal alpha and beta (but not delta) coherences in association 
with an improvement of motor symptoms in PD patients (Moazami-Goudarzi et al., 2008; 
Silberstein et al., 2005). Also, intrahemispheric fronto-temporo-central delta and theta 
coherences were higher in DLB than in ADD patients (Andersson et al., 2008). Finally, 
global alpha coherence over the whole scalp was lower in DLB than ADD patients while 
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global delta coherence was higher in the former than in the latter group (Andersson et al., 
2008).  
These mixed results in the literature confirms the complexity of the interactions 
and confounds related to comorbidities (e.g. depression, behavioral symptoms), 
psychoactive drugs, different stages of the diseases, and different levels of the 
impairment in cholinergic and dopaminergic systems in ADD, DLB, and PDD patients. A 
possible design to disentangle these variables may be a longitudinal study in de-novo 
ADD, DLB, and PDD patients, free from major depression, to be undergone to rsEEG 
recordings before and after chronic administration of cholinergic and dopaminergic 
therapy. In these patients, levels of the impairment in cholinergic and dopaminergic 
systems may be measured by PET using radio ligands for cholinergic markers and 
DATSCAN, respectively. Of note, those radio ligands for cholinergic markers such as 
[11C]MP4A and [11C]PMP PET for acetylcholinesterase (AChE), [123I]5IA SPECT for the 
α4β2 nicotinic acetylcholine receptor and [123I]IBVM SPECT for the vesicular acetylcholine 
transporter have shown that cortical AChE was reduced in PDD and ADD patients in 
relation with the level of performance in attention and working memory tests (see a 
review in Roy et al., 2016). 
 
Methodological remarks 
In the reference study carried out in the same populations (Babiloni et al., 2017), 
we discussed some methodological limitations of this retrospective and explorative study. 
Summarizing, these limitations include the relatively small number of the patients (N = 
34-42) and the lack of (1) unified experimental recording protocol, (2) harmonized 
hardware for EEG recordings and neuroimaging, (3) extensive neuroimaging (e.g. 
DATSCAN), (4) neuropsychological battery (e.g. ADAS-Cog) in all clinical Units (e.g. the 
MMSE score may be not equally sensitive to global cognitive deficits in all 
neurodegenerative dementing disorders), (5) groups of patients with prodromal stages of 
the disease (i.e. no anti-dementia pharmacological therapy), and (6) repeated recordings 
over time.  
Here two additional methodological limitations are discussed. In the present 
study, 128 Hz sampling rate was used for the data analysis as a frequency available in all 
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clinical units of this international Consortium. Noteworthy, this sampling rate is not 
optimal for the analysis of gamma band, especially for frequencies higher than 40 Hz. An 
optimal setting of EEG recording parameters may use 256 or 512 Hz to cover the whole 
gamma rage and high-frequency oscillations > 40 Hz. However, the use of 128 Hz 
sampling rate did not affect the main findings of the present study found at delta and 
alpha frequency bands, ranging < 13 Hz. Furthermore, the Figures 2 and 3 of this article 
showed that the LLC solutions at beta 2 and gamma (20-40 Hz) bands were negligible in 
the present experimental conditions (i.e. eyes closed resting state). Therefore, it is not 
probable that relevant effects may be observed at higher frequencies in these conditions. 
In this study, another specific methodological limitation should be remarked. We 
used the toolbox LLC of eLORETA freeware (Pascual-Marqui et al., 2011) to estimate the 
functional connectivity between rsEEG cortical sources in Nold, ADD, PDD, and DLB 
groups of subjects. Specifically, LLC estimates and removes zero-lag phase source 
interactions from the total linear connectivity in pairs of EEG cortical sources to mitigate 
at least in part the effects of head volume conduction (Pascual-Marqui et al., 2011). As a 
bivariate measurement of lagged interactions between two cortical sources, LLC may not 
remove the “common drive” effect of a third brain source sending action potentials to 
that pair of sources examined. This effect may cause a number of “false” connections 
between pairs of scalp sensors or source solutions in the readouts of the procedures 
(especially bivariate) used for estimation of EEG functional connectivity. Typically, those 
“false” connections are characterized by a “random” spatial topology. For this reason, we 
performed 4 control analyses to test the hypotheses that the present LLC solutions did 
not show a “random” spatial scheme between the pairs of ROIs in the Nold and the 
dementia groups. As an example, we used the LLC solutions computed for alpha rhythms. 
Results of these control analyses were not in line with a “random” topology of the pattern 
of functional EEG source connectivity of alpha rhythms (as reference dominant rsEEG 
rhythms) in the Nold group. In the same vein, they did not show a “random” topology of 
the pattern of the differences in functional EEG source connectivity of alpha rhythms 
between the Nold and the dementia groups. However, the present results did not exclude 
that part of the shown effects were due to common drive phenomenon. Therefore, future 
investigations will have to address this issue on simulated and real data, allowing a better 
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understanding of the reliability and validity of the LCC estimates of rsEEG source 
connectitivty with reference to head volume condution and common drive/source effects. 
In this line, other EEG functional connectivity metrics, which are related to Granger 
causality, may be helpful to exclude the spurious lagged connectivity due to head volume 
condution and common drive effects. These are the directed transfer function (DTF;  
Kamiński and Blinowska, 1991) and the partial directed coherence (PDC; Baccalá and 
Sameshima, 2001). In the original implementations, both procedures are grounded on 
phase differences between EEG signals recorded at scalp electrodes. Among them, DTF 
shows not only direct, but also cascade flows, namely in case of propagation when there 
is a phase difference between signals (Blinowska, 2011). Another interesting procedure is 
the computation of “isolated effective coherence”, estimating the partial coherence in 
the eLORETA source space under a multivariate autoregressive model (Pasqual-Marqui et 
al., 2014). 
 
Conclusions 
Previous evidence showed abnormal markers of cortical neural 
“synchronization/desynchronization” in quiet wakefulness in ADD, DLB, and PDD patients, 
as revealed by posterior sources of delta (<4Hz) and alpha (8-12 Hz) rhythms (Babiloni et 
al., 2017). We proposed that those markers might probe the neurophysiological reserve in 
those patients. The present exploratory study tested the hypothesis that another class of 
markers might probe the patients’ neurophysiological reserve, namely the markers of 
“functional cortical connectivity.” These markers might be especially informative in AD 
individuals, supposed to suffer from a “disconnection cortical syndrome” (Bokde et al., 
2009; Teipel et al., 2016).  
At the group level, the present results indicated that interhemispheric and 
intrahemispheric LLC solutions in widespread delta sources were abnormally higher in the 
ADD group and, surprisingly, normal in the DLB and PDD groups. Intrahemispheric LLC 
solutions were reduced in widespread alpha sources dramatically in the ADD group, 
markedly in the DLB group, and moderately in the PDD group. Furthermore, the 
interhemispheric LLC solutions showed lower values in the ADD and DLB groups than the 
PDD group.  
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At the individual level, AUROC curves of LLC solutions in alpha sources exhibited 
better classification accuracies for the discrimination of ADD vs. Nold individuals (0.84) 
than for Nold vs. DLB (0.78) and Nold vs. PDD alpha (0.75).  
    These findings suggest that functional cortical connectivity in both delta and 
alpha sources might unveil more compromised neurophysiological reserve in Alzheimer’s 
than Lewy bodies’ dementia, at both group and individual levels. This effect might occur 
Interhemisphericly and Intrahemisphericly, with more discrimination between the ADD 
and DLB groups Interhemisphericly.  
These findings motivate future prospective, multi-center studies using a detailed 
evaluation of the patients’ cognitive status, harmonized EEG hardware systems, and 
unique data collection protocols. Those future studies will aim to cross-validate the 
present results and improve our understanding of the effects of neurodegenerative 
dementing disorders on the rsEEG markers of the neurophysiological reserve, namely 
those of “synchronization/desynchronization” and “functional cortical connectivity.” An 
exciting hypothesis for those studies is that the combination of 
“synchronization/desynchronization” and “functional cortical connectivity” markers might 
be valid topographic biomarkers of ADD, DLB, and PDD for clinical applications and 
research (i.e. the stratification of patients based on an index of neurophysiological reserve 
and the evaluation over time of the mechanistic effect of interventions).  
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Table legends 
Table 1. Mean values (± standard error mean, SE) of the demographic and clinical data as 
well as the results of their statistical comparisons (p < 0.05) in the groups of normal 
healthy elderly (Nold) subjects and patients with dementia due to Alzheimer’s disease 
(ADD), Parkinson’s disease (PDD), and Lewy bodies (DLB). Legend: MMSE = Mini Mental 
State Evaluation; M/F = males/females; n.s. = not significant (p > 0.05). 
 
Table 2. Talairach coordinates of the centroid voxel for the left and right frontal, central, 
parietal, occipital and temporal regions of interest (ROIs) 
 
Table 3. Mean values (± SE) of transition frequency (TF) and individual alpha frequency 
(IAF) peak of the rsEEG power density spectra in the Nold, ADD, PDD, and DLB groups. The 
Table also reports the p-values derived from the statistical comparisons of these values 
between the groups. See the Methods section for a definition of the TF and IAF. Legend: 
ADD, Alzheimer's disease with dementia; PDD, Parkinson's disease with dementia; DLB, 
dementia with Lewy body; rsEEG, resting state eyes-closed electroencephalographic; SE, 
standard error of the mean. 
 
Table 4. Results of the classification among Nold, ADD, PDD, and DLB individuals based on 
the lagged linear connectivity (LLC) solutions computed in eLORETA cortical sources of 
resting state electroencephalographic (rsEEG) rhythms at individual delta and alpha 
frequency bands. These LLC solutions were those showing statistically significant 
differences among the four groups in the main statistical analysis (i.e. Nold, ADD, PDD, 
DLB). The classification rate is computed by the analysis of area under the receiver 
operating characteristic (AUROC) curve. The table reports the classification indexes 
(Sensitivity, Specificity, Accuracy) for all the LLC solutions in delta and alpha sources 
having a value higher than 0.70 in the AUROC curves. Highlighted in red type are the best 
classification results for each LLC solutions in the classifications of interest, namely Nold 
vs. ADD individuals, Nold vs. DLB individuals, and Nold vs. PDD individuals. 
 
Table 5 Duncan post-hoc relative to a statistically significant main effect (F = 35.9, p < 
0.00001)  for the factor Pair of ROIs  (frontal-central, frontal-temporal, central-temporal, 
frontal-parietal, central-parietal, temporal-parietal, frontal-occipital, central-occipital, 
temporal-occipital, and parietal-occipital) in an ANOVA design focused on the 
intrahemispheric LLC solutions computed in eLORETA cortical sources of alpha rsEEG 
rhythms of the Nold group (p < 0.05). 
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Figure legends 
Figure 1. Representative EEG waveforms (10 s) on Fz and Pz scalp electrodes for Nold, 
ADD, PDD, and DLB subjects. These subjects were carefully selected to represent the 
general features of EEG waveforms in the groups of individuals investigated in the present 
study.  
 
Figure 2. Mean values (± standard error mean, SE) of the interhemispheric lagged linear 
connectivity (LLC) solutions computed in eLORETA cortical sources of resting state 
electroencephalographic rhythms (rsEEG) relative to a statistically significant ANOVA 
interaction effect (F = 3.2, p < 0.0001) among the factors Group (Nold, ADD, PDD, and 
DLB), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and 
Region of interest, ROI (frontal, central, parietal, occipital, and temporal). Legend: the 
rectangles indicate the ROIs and frequency bands in which the interhemispheric LLC 
solutions presented statistically significant differences among the four groups of subjects 
(p < 0.05). 
 
Figure 3. Mean values (± SE) of the Intrahemispheric LLC solutions computed in eLORETA 
cortical sources of rsEEG rhythms relative to a statistically significant ANOVA interaction 
effect (F = 5.4, p < 0.0001) among the factors Group (Nold, ADD, PDD, and DLB), Band 
(delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, 
central, parietal, occipital, and temporal). Legend: the rectangles indicate the ROIs and 
frequency bands in which the Intrahemispheric LLC solutions presented statistically 
significant differences among the four groups of subjects (p < 0.05). 
 
Figure 4. Individual values of the interhemispheric LLC solutions computed in eLORETA 
cortical sources of alpha rhythms showing statistically significant (p < 0.05) differences 
between the Nold, ADD, PDD, and DLB groups (i.e. parietal, occipital, and temporal alpha 
2; parietal, occipital, and temporal alpha 3). Noteworthy, the Grubbs' test showed no 
outliers from those individual values of the interhemispheric LLC solutions (arbitrary 
threshold of p < 0.0001). 
 
Figure 5. Individual values of the intrahemispheric LLC solutions computed in eLORETA 
cortical sources of alpha rhythms showing statistically significant (p < 0.05) differences 
between the Nold, ADD, PDD, and DLB groups (i.e. frontal, central, parietal, occipital, and 
temporal alpha 2; central, parietal, occipital, and temporal alpha 3). Noteworthy, the 
Grubbs' test showed no outliers from those individual values of the intra-hemispherical 
LLC of eLORETA rsEEG cortical sources (arbitrary threshold of p < 0.0001). 
 
Figure 6. Scatterplots showing the correlation between LLC solutions of computed in 
eLORETA cortical sources of alpha rhythms and the MMSE score in the Nold, ADD, PDD, 
and DLB subjects as a whole group. The Spearman test evaluated the hypothesis of that 
correlation (Bonferroni’s correction at p < 0.05). The r and p values are reported within 
the diagram.  
 
Figure 7. (Top): Receiver operating characteristic (ROC) curve illustrating the classification 
of the ADD and Nold individuals based on the interhemispheric LLC solutions computed in 
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temporal alpha 2 cortical sources. The area under the ROC (AUROC) curve was 0.84 (e.g. 1 
= 100%), indicating a good classification accuracy for the ADD and Nold individuals. 
(Middle): ROC curve illustrating the classification of the PDD and Nold individuals based 
on the interhemispheric LLC solutions computed in temporal alpha 3 cortical sources. The 
AUROC was 0.72, indicating a moderate classification accuracy of the PDD and Nold 
individuals. (Bottom): ROC curve illustrating the classification of the DLB and Nold 
individuals based on the intrahemispheric LLC solutions computed in central alpha 2 
cortical sources. The AUROC was 0.78, indicating a moderate classification accuracy of the 
DLB and Nold individuals. 
 
Figure 8. (A): Mean values (± SE) of the Intrahemispheric LLC solutions computed in 
eLORETA cortical sources of alpha rsEEG rhythms relative to a statistically significant main 
effect (F = 35.9, p < 0.00001)  for the factor Pair of ROIs  (frontal-central, frontal-temporal, 
central-temporal, frontal-parietal, central-parietal, temporal-parietal, frontal-occipital, 
central-occipital, temporal-occipital, and parietal-occipital) in Nold subjects. (B): Mean 
values (± SE) of the intrahemispheric LLC solutions computed in eLORETA cortical sources 
of alpha rsEEG rhythms relative to a statistically significant ANOVA interaction effect (F = 
5.7, p < 0.00001) among the factors Group (Nold and ADD), and Pair of ROIs (frontal-
central, frontal-temporal, central-temporal, frontal-parietal, central-parietal, temporal-
parietal, frontal-occipital, central-occipital, temporal-occipital, and parietal-occipital). 
Legend: the rectangles indicate the Pair of ROIs which the intrahemispheric LLC solutions 
presented statistically significant differences between Nold and ADD groups (p < 0.05). 
(C): Mean values (± SE) of the Intrahemispheric LLC solutions computed in eLORETA 
cortical sources of alpha rsEEG rhythms relative to a statistically significant ANOVA 
interaction effect (F = 2.5, p < 0.01) among the factors Group (Nold and PDD), and Pair of 
ROIs (frontal-central, frontal-temporal, central-temporal, frontal-parietal, central-parietal, 
temporal-parietal, frontal-occipital, central-occipital, temporal-occipital, and parietal-
occipital). Legend: the rectangles indicate the Pair of ROIs which the intrahemispheric LLC 
solutions presented statistically significant differences between Nold and PDD groups (p < 
0.05). (D): Mean values (± SE) of the intrahemispheric LLC solutions computed in eLORETA 
cortical sources of alpha rsEEG rhythms relative to a statistically significant ANOVA 
interaction effect (F = 4.2, p < 0.00005) among the factors Group (Nold and DLB), and Pair 
of ROIs (frontal-central, frontal-temporal, central-temporal, frontal-parietal, central-
parietal, temporal-parietal, frontal-occipital, central-occipital, temporal-occipital, and 
parietal-occipital). Legend: the rectangles indicate the Pair of ROIs which the 
intrahemispheric LLC solutions presented statistically significant differences between Nold 
and DLB groups (p < 0.05). 
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Table 1 
MEAN VALUES (± STANDARD ERROR MEAN, SE) OF DEMOGRAPHIC DATA AND GLOBAL 
COGNITIVE STATUS (MMSE SCORE ) 
 Nold  ADD  PDD  DLB  Statistical analysis  
N 40 42 42  34     
Age 
72.9 
 (± 1.1 SE) 
73.3  
(± 1.0 SE) 
74.1  
(± 1.1SE) 
75.1  
(± 1.1 SE) 
ANOVA: n.s.  
Gender 
(M/F)  
16/24  17/25  18/24 11/23  Kruskal-Wallis: n.s.  
Education  
8.5 
 (± 0.6 SE) 
8.1  
(± 0.8 SE) 
7.0  
(± 0.6 SE) 
7.4  
(± 0.8 SE) 
ANOVA: n.s.  
MMSE  
28.7  
(± 0.2 SE) 
18.9  
(± 0.6 SE) 
18.8 
 (± 0.7 SE) 
18.6  
(± 0.8 SE) 
Kruskal-Wallis: H=88.7, 
p<0.00001 
(Nold>ADD, PDD, DLB)  
 
59 
 
Table 2 
Regions of interest (ROIs) X Y Z 
Left frontal  -27.9 35.2 10.6 
Left central -32.6 -12.7 52.3 
Left parietal  -33.2 -53.4 39.9 
Left occipital -22.2 -81.0 5.2 
Left temporal  -49.6 -22.9 -13.9 
Right frontal  27.8 35.4 12.3 
Right central 32.5 -12.4 52.5 
Right parietal  30.2 -53.5 40.9 
Right occipital 20.4 -81.5 5.1 
Right temporal  50.2 -21.1 -14.2 
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Table 3 
MEAN VALUES (± SE) OF TRANSITION THETA/ALPHA FREQUENCY (TF) AND INDIVIDUAL 
ALPHA FREQUENCY (IAF) PEAK  
 Nold ADD PDD DLB Statistical analysis 
TF 
5.8  
(± 0.2 SE) 
5.9 
 (± 0.2 SE) 
4.9 
 (± 0.2 SE) 
5.0 
 (± 0.2 SE) 
ANOVA: F = 10.4, p < 0.00001 
(Nold, ADD > PDD, DLB)  
IAF 
9.0  
(± 0.2 SE) 
8.8  
(± 0.3 SE) 
7.3  
(± 0.3 SE) 
7.3  
(± 0.3 SE) 
ANOVA: F = 14.9, p < 0.00001 
(Nold > ADD > PDD, DLB)  
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Table 4 
CLASSIFICATION OF NOLD, ADD, PDD, AND DLB INDIVIDUALS BASED ON LAGGED LINEAR 
CONNECTIVIY OF rsEEG CORTICAL  SOURCES  
Nold vs. 
ADD  
Lagged linear connectivity (LLC) Sensitivity Specificity Accuracy AUROC  
Occipital delta interhemispheric 61.9% 77.5% 69.7% 0.70 
Parietal alpha 2 interhemispheric 83.3% 67.5% 75.4% 0.76 
Occipital alpha 2 interhemispheric 61.9% 80% 71% 0.74 
Temporal alpha 2 interhemispheric 85.7% 67.5% 76.6% 0.81 
Parietal alpha 3 interhemispheric 73.8% 72.5% 73.2% 0.79 
Occipital alpha 3 interhemispheric 88.1% 62.5% 75.3% 0.77 
Temporal alpha 3 interhemispheric 78.6% 77.5% 78.1% 0.84 
Frontal alpha 2 intrahemispheric 57.1% 85.0% 71.1% 0.73 
Central alpha 2 intrahemispheric 69.1% 82.5% 75.8% 0.77 
Parietal alpha 2 intrahemispheric 71.4% 77.5% 74.5% 0.77 
Occipital alpha 2 intrahemispheric 69.1% 80.0% 74.5% 0.75 
Temporal alpha 2 intrahemispheric 69.1% 80.0% 74.5% 0.74 
Central alpha 3 intrahemispheric 64.3% 87.5% 75.9% 0.79 
Parietal alpha 3 intrahemispheric 61.9% 87.5% 74.7% 0.79 
Occipital alpha 3 intrahemispheric 64.3% 82.5% 73.4% 0.77 
Temporal alpha 3 intrahemispheric 47.6% 95.0% 71.3% 0.77 
Nold vs. 
PDD 
Temporal alpha 2 interhemispheric 82.3% 70% 76.2% 0.75 
Temporal alpha 3 interhemispheric 73.8% 65% 69.4% 0.72 
Nold vs. 
 DLB 
Parietal alpha 2 interhemispheric 82.4% 67.5% 74.9% 0.76 
Temporal alpha 2 interhemispheric 76.5% 67.5% 72% 0.72 
Parietal alpha 3 interhemispheric 79.4% 70.0% 74.7% 0.75 
Temporal alpha 3 interhemispheric 91.2% 57.5% 74.3% 0.77 
Central alpha 2 intrahemispheric 83.5% 65% 74.3% 0.78 
Parietal alpha 2 intrahemispheric 73.5% 77.5% 75.5% 0.77 
Occipital alpha 2 intrahemispheric 70.6% 75.0% 72.8% 0.75 
Temporal alpha 2 intrahemispheric 85.3% 57.5% 71.4% 0.74 
Central alpha 3 intrahemispheric 73.5% 72.5% 73.0% 0.76 
Parietal alpha 3 intrahemispheric 94.1% 60.0% 77.1% 0.77 
Occipital alpha 3 intrahemispheric 70.6% 70.0% 70.3% 0.74 
Temporal alpha 3 intrahemispheric 76.5% 65.0% 70.7% 0.75 
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Table 5 
 Frontal- 
Central 
Frontal- 
Temporal 
Central- 
Temporal 
Frontal- 
Parietal 
Central-
Parietal 
Temporal- 
Parietal 
Frontal- 
Occipital 
Central- 
Occipital 
Temporal- 
Occipital 
Parietal 
Occipital 
Frontal- 
Central 
 <0.001 <0.00001 n.s. <0.00001 <0.00001 n.s. <0.00001 <0.00001 <0.00001 
Frontal- 
Temporal 
<0.001  <0.05 <0.0001 <0.001 <0.00001 <0.005 <0.01 <0.0005 <0.00001 
Central- 
Temporal 
<0.00001 <0.05  <0.00001 n.s <0.01 <0.00001 n.s n.s <0.00001 
Frontal- 
Parietal 
n.s. <0.0001 <0.00001  <0.00001 <0.00001 n.s <0.00001 <0.00001 <0.00001 
Central-
Parietal 
<0.00001 <0.001 n.s <0.00001  n.s <0.00001 n.s n.s <0.00001 
Temporal- 
Parietal 
<0.00001 <0.00001 <0.01 <0.00001 n.s  <0.00001 n.s n.s <0.00005 
Frontal- 
Occipital 
n.s. <0.005 <0.00001 n.s <0.00001 <0.00001  <0.00001 <0.00001 <0.00001 
Central- 
Occipital 
<0.00001 <0.01 n.s <0.00001 n.s n.s <0.00001  n.s <0.00001 
Temporal- 
Occipital 
<0.00001 <0.0005 n.s <0.00001 n.s n.s <0.00001 n.s  <0.00001 
Parietal 
Occipital 
<0.00001 <0.00001 <0.00001 <0.00001 <0.00001 <0.00005 <0.00001 <0.00001 <0.00001  
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